← Back

Clinical Medicine and Surgery I · Exam 7 — Clin Med Pro Guide

PAJ 5500 Clinical Medicine and Surgery I · Class of 2028

Respiratory II block · 45 conditions across 6 lectures · Dr. Carter’s Clin Med Pro Study Tip, ten fields per condition

How to use this guide

Dr. Carter’s Clin Med Pro Study Tip (Hypotension deck, slide 7) lists what to learn for every condition. Each card below answers those ten fields:

  1. Name of Condition
  2. Definition
  3. Etiology (cause)
  4. Epidemiology (who)
  5. Risk Factors
  6. Pathology
  7. Clinical Manifestation
  8. Diagnosis
  9. Treatment/Therapy
  10. Mortality ★

Every field comes from the lecture slides only. Where a deck is silent the card says Not covered in the lecture rather than filling the gap from elsewhere (61 of 450 fields in this exam; Mortality alone: 19 of 45). Slide numbers follow each field. Cards open closed; tap one to read it.

The ★ on Mortality is on the original study-tip slide: fill it when a figure exists. A ★ highlighted phrase inside a field is a fact the professor emphasized in the lecture recording, carried over from this exam’s study guide.

Lecture 40 · Obstructive Sleep Apnea and Obesity Hypoventilation Syndrome

Chand Shah, MPAS, PA-C · 3 conditions · source: CMS I Obstructive Sleep Apnea & Obesity Hypoventilation Syndrome - Shah Fallsv.pptx

Note: Built from the slides; the stars are what she stressed in the 2 November recording. Lecture 39 (Phases of Sleep) has no disease and so no Clin Med Pro card. The STOP-Bang questionnaire is a picture on slide 17. Where the slides give two neck sizes (17 and 16 inches by sex as a risk factor; 16 inches for anyone on STOP-Bang) each is kept with its own tool. The apnea-hypopnea severity bands are in the speaker notes only and are left out. Dosing is left out.
Obstructive sleep apnea (OSA)★ Professor emphasized

★ Diagnosis “as simple as possible, five or more plus a symptom or 15 or more”; the sleep study is the gold standard and the home kit checks only obstructive apnea; “patient education is like the most important thing that we can do” (CPAP works but patients dislike it); severe disease needs CPAP, not an oral appliance; postmenopausal women carry more risk, “an important thing.”

Name of Condition
Obstructive sleep apnea (OSA) Slides 4–5
Definition
Sleep-disordered breathing from upper airway narrowing: obstructive apneas (no airflow despite continued respiratory effort; airflow down 90% or more for at least 10 seconds) and hypopneas (slowed, shallow breathing in episodes of 10 seconds or longer) Slides 3, 5
Etiology (cause)
Narrowing of the upper airway by excessive soft tissue or structural abnormalities Slide 5
Epidemiology (who)
The most common form of sleep-disordered breathing; prevalence increases with age; sleep-disordered breathing is more common after menopause than before Slide 5
Risk Factors
Obesity, macroglossia, micrognathia, retrognathia, neck circumference 17 inches or more (men) or 16 (women), enlarged tonsils, increasing age, male sex, family history, alcohol or sedatives, hypothyroidism Slide 6
Pathology
Upper airway collapse during sleep while effort continues; untreated: increased sympathetic tone, bradycardia, blood pressure variability, arrhythmias, raised C-reactive protein, cortisol and proinflammatory cytokines Slides 3, 21–22, 24
Clinical Manifestation
Daytime sleepiness, unrefreshing sleep, witnessed apnea, snorting or gasping awakenings, loud habitual snoring, morning headache, nocturia, poorly controlled hypertension, poor concentration, low libido, night sweats; exam: obesity, large neck, enlarged tonsils, crowded posterior oropharynx Slide 7
Diagnosis
Split-night or all-night polysomnogram (gold standard); 5 or more predominantly obstructive events per hour plus a symptom, or 15 or more events, not explained by another condition; apnea-hypopnea and respiratory disturbance indices; thyroid-stimulating hormone if hypothyroidism is suspected; home kits assess only obstructive apnea and may miss mild disease, so use a polysomnogram with significant cardiopulmonary disease, neuromuscular weakness, awake hypoventilation or hypoxemia, stroke, long-term opioids, severe insomnia or a suspected non-obstructive sleep disorder; STOP-Bang (snoring, tired, observed, pressure, body mass index over 35, age over 50, neck 16 inches, gender male) preoperatively, not for community screening Slides 8–9, 16–17
Treatment/Therapy
Continuous positive airway pressure (most effective); autotitrating pressure without significant comorbidities; positional therapy; oral appliance (not severe disease, not without teeth); nasal expiratory device; stimulants (modafinil or armodafinil; caution with cardiovascular, hepatic, psychiatric disease; lower doses in the elderly); nasal steroids; surgery (tracheostomy is a cure); weight loss; avoid alcohol and sedatives; refer to a sleep physician Slides 11–13, 15
Mortality ★
Untreated: 2.5 times the driving accidents, 3 to 6 times the risk of sudden cardiac death at night, high heart failure mortality, 3 times the risk of hypertension; pulmonary hypertension, stroke, insulin resistance and diabetes, arrhythmias, ischemic heart disease, fatty liver (2 to 3 times), reflux (75 to 100%); lower mortality in the elderly, who compensate Slides 18–22
Central sleep apnea (CSA)★ Professor emphasized1 not covered

★ “I really want everyone to understand these risk factors are very different” (heart failure, stroke, opioids, high altitude, CPAP use), “because the treatment for central sleep apnea is really taking care of their risk factors”; CPAP first, then ASV, never with poor left ventricular function; home testing is not effective here.

Name of Condition
Central sleep apnea (CSA) Slide 23
Definition
Sleep-disordered breathing in which the brainstem stops sending signals to breathe: no airflow and no respiratory effort Slides 3, 24
Etiology (cause)
Increased sensitivity to carbon dioxide causing unstable breathing, hyperventilation alternating with apnea; in heart failure, Cheyne-Stokes breathing from a prolonged circulation delay to the carotid chemoreceptors Slide 24
Epidemiology (who)
Less common than obstructive sleep apnea Slide 24
Risk Factors
Congestive heart failure, stroke, opioid medications, hypoxia, high altitude, use of continuous positive airway pressure Slide 24
Pathology
Airflow stops because respiratory effort is absent or decreased (in obstructive apnea the airway collapses while effort continues) Slides 3, 24
Clinical Manifestation
Insomnia, frequent awakenings, nocturnal dyspnea, nonrestorative sleep, daytime sleepiness; snoring less common than in obstructive apnea; sounds very similar to obstructive apnea Slide 25
Diagnosis
Polysomnography (home testing not sufficient): repetitive apneas without thoracic-abdominal excursion Slide 26
Treatment/Therapy
Treat the cause (optimize heart failure therapy, reduce opioids, descend from altitude); continuous positive airway pressure first; adaptive servo-ventilation if it fails, avoided especially in heart failure with reduced ejection fraction Slide 26
Mortality ★
Not covered in the lecture
Obesity hypoventilation syndrome (Pickwickian syndrome)★ Professor emphasized

★ “Diagnosis of exclusion is kind of the big thing”; “the gender does not matter here”; weight loss plus BiPAP or CPAP, “first line, first line, first line”; cardiovascular disease is the leading cause of death.

Name of Condition
Obesity hypoventilation syndrome (OHS), Pickwickian syndrome Slide 28
Definition
Awake alveolar hypoventilation (raised awake arterial carbon dioxide) in an obese person that cannot be attributed to another condition; a diagnosis of exclusion Slides 28, 32
Etiology (cause)
Obesity with reduced lung function and reduced inspiratory muscle strength; severe obstructive sleep apnea may be present (70% have severe obstructive symptoms) Slides 29–30
Epidemiology (who)
More likely as body mass index rises; patients may present in their 50s and 60s; male sex is not a risk factor; 90% have coexisting obstructive apnea symptoms (70% severe), 10% coexisting sleep hypoventilation (older women) Slides 28–30
Risk Factors
Central obesity (high waist-to-hip ratio), reduced lung function from obesity, reduced inspiratory muscle strength, severe obstructive sleep apnea Slide 29
Pathology
Awake hypoventilation with hypercapnia; late disease: hypoxemic hypercapnic respiratory failure and right-sided heart failure from pulmonary hypertension Slides 28, 30
Clinical Manifestation
Nonspecific: obese (body mass index over 30) and hypersomnolent, loud snoring, choking, fatigue, poor memory, small oropharynx, thick neck, dyspnea on exertion, facial plethora, elevated jugular venous pressure, hepatomegaly, pedal edema Slides 30–31
Diagnosis
Screen when awake saturation is 94% or less or the overnight lowest is below 80%, or with unexplained dyspnea, right heart failure, facial plethora or a raised bicarbonate (over 27: get an arterial blood gas). Diagnose: body mass index over 30, awake arterial carbon dioxide over 45 mm Hg, other causes excluded; labs (metabolic panel, blood count, thyroid, pulmonary function, chest film, toxicology); gold standard polysomnography with continuous nocturnal carbon dioxide monitoring Slides 31–32
Treatment/Therapy
Multidisciplinary; first line weight loss plus continuous positive airway pressure (with obstructive apnea) or bilevel positive airway pressure (with sleep hypoventilation) and lifestyle change; second line tracheostomy with nocturnal ventilation, bariatric surgery, medications after diet and exercise fail; refer to a sleep specialist Slides 33–34
Mortality ★
High morbidity and mortality; progresses untreated; cardiovascular disease is the leading cause of death; more hospital and intensive care use; poor prognosis with significant awake hypoxemia at diagnosis Slide 35

Lecture 41 · Inflammatory Lung Diseases

Rob Gray, DMSc, PA-C (guest lecturer) · 9 conditions · source: Inflammatory Lung Disease 2026.pptx

Note: Built from the slides plus the lecturer's narrated recording, which only chooses which facts to star. Slides 72-74 (acute respiratory distress syndrome) are AI-made pictures with typos; the plateau pressure figure on slide 74 ('under 50 cm H2O') is left out. He said not to memorize the cause and drug charts and that the rare idiopathic subtypes are not test material. Dosing is left out.
Idiopathic pulmonary fibrosis (IPF)★ Professor emphasized1 not covered

★ He called idiopathic pulmonary fibrosis "kind of the most common thing"; the four over-65 criteria allow a diagnosis without a surgical lung biopsy.

Name of Condition
Idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonia Slide 35
Definition
The most common idiopathic (fibrosing) interstitial pneumonia: pulmonary fibrosis with no associated cause Slides 32, 35
Etiology (cause)
Unknown; smoking is the cause in the majority of cases Slides 35, 37
Epidemiology (who)
★ The most common subtype of idiopathic interstitial pneumonia, itself the most common diagnosis among patients with interstitial lung disease; 67 to 75% of patients with idiopathic pulmonary fibrosis and familial lung fibrosis have smoked; the four criteria that make a surgical lung biopsy unnecessary apply over 65 Slides 31–32, 35
Risk Factors
Smoking (67 to 75% of patients with idiopathic pulmonary fibrosis and familial lung fibrosis have smoked; smoking is the cause in the majority of cases) Slides 31, 37
Pathology
As in all fibrosis: inflammatory cells gather in the alveolar walls, alveolitis drives fibroblast production and collagen causes the fibrosis; CT shows diffuse, patchy fibrosis with pleural-based honeycombing Slides 6, 34
Clinical Manifestation
Insidious dry cough, exertional dyspnea, fatigue and malaise; clubbing, bibasilar inspiratory crackles, tachypnea, reduced chest expansion Slide 33
Diagnosis
Restrictive pattern (normal or increased ratio, decreased lung volumes); chest film with progressive fibrosis over several areas; CT with diffuse patchy fibrosis and pleural-based honeycombing; lavage or biopsy as needed. Over 65 with idiopathic disease and crackles, restrictive physiology, progressive fibrosis over years and honeycombing on high-resolution CT: 90% confidence, no surgical lung biopsy needed Slides 34–35
Treatment/Therapy
Controversial: nothing has improved survival or quality of life compared with no treatment; smoking cessation is critical Slide 37
Mortality ★
Not covered in the lecture
Idiopathic interstitial pneumonias (other subtypes)
Name of Condition
Idiopathic (fibrosing) interstitial pneumonias Slide 31
Definition
Interstitial pneumonias of unknown cause defined by histopathologic pattern Slide 31
Etiology (cause)
Unknown Slide 30
Epidemiology (who)
Taken together the most common diagnosis among interstitial lung diseases; idiopathic pulmonary fibrosis is the most common subtype Slides 31–32
Risk Factors
Smoking (67 to 75% of patients with idiopathic pulmonary fibrosis and familial lung fibrosis have smoked) Slide 31
Pathology
Patterns: idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, respiratory bronchiolitis-associated interstitial lung disease, lymphoid interstitial pneumonia, acute interstitial pneumonitis Slide 31
Clinical Manifestation
Dry cough, exertional dyspnea, constitutional symptoms; symptoms vary by subtype Slides 33, 38
Diagnosis
Suspect in unexplained interstitial lung disease; may require biopsy; age, sex, prodrome, imaging and histology together Slides 31–32
Treatment/Therapy
Depends on the subtype; corticosteroids may be used in cryptogenic organizing pneumonia (bronchiolitis obliterans organizing pneumonia), lymphoid and nonspecific interstitial pneumonia Slides 32, 38
Mortality ★
Prognosis depends on the subtype diagnosed Slide 32
Pulmonary fibrosis with connective tissue disease3 not covered
Name of Condition
Pulmonary fibrosis associated with connective tissue disorders Slide 18
Definition
An inflammatory and fibrotic interstitial response in autoimmune (connective tissue) disease Slide 18
Etiology (cause)
Systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, systemic sclerosis, Sjogren syndrome, polymyositis-dermatomyositis, scleroderma; methotrexate, used to treat many of them, has been implicated as a cause of interstitial lung disease Slide 18
Epidemiology (who)
Not covered in the lecture
Risk Factors
The underlying autoimmune disease; methotrexate therapy Slide 18
Pathology
Inflammatory and fibrotic lung response Slide 18
Clinical Manifestation
The general interstitial lung disease picture (no slide specific to connective tissue disease): progressive exertional dyspnea, persistent nonproductive cough; crackles, clubbing Slides 23–24
Diagnosis
High antinuclear antibody (collagen vascular disease); restrictive pulmonary function; imaging Slides 25–26, 29
Treatment/Therapy
Not covered in the lecture
Mortality ★
Not covered in the lecture
Sarcoidosis★ Professor emphasized

★ "Sarcoid, you could see questions about"; lupus pernio with a dry cough is a red flag; know the lab clues and the stages.

Name of Condition
Sarcoidosis Slide 39
Definition
A multi-organ disease of idiopathic cause with noncaseating granulomatous inflammation, most often of the lungs and lymphatic system Slide 39
Etiology (cause)
Unknown; environmental triggers (viral, bacterial, mycobacterial, inhaled agents, mold) in a genetically predisposed person Slides 39–40
Epidemiology (who)
Granulomatous lung inflammation in about 90%; higher in North American Black and Northern European white people; more often women; onset in the third and fourth decades Slides 39–40
Risk Factors
Genetic predisposition plus environmental exposure Slide 39
Pathology
Noncaseating granulomas (T lymphocytes, macrophages, epithelioid cells) in lungs, nodes, eyes, skin, liver, spleen, salivary glands, heart, nervous system Slides 20, 39
Clinical Manifestation
Cough, insidious dyspnea, chest discomfort, malaise, fever, weakness, weight loss, nontender lymphadenopathy; erythema nodosum, parotid enlargement, hepatosplenomegaly, crackles, ★ lupus pernio (painful skin sores on the face) Slides 42–43
Diagnosis
Chest film: symmetric bilateral hilar and right paratracheal adenopathy, stages I to IV; ★ elevated sedimentation rate and angiotensin-converting enzyme (40 to 80%), hypercalcemia (5%), hypercalciuria, eosinophilia, leukopenia; transbronchial or fine-needle node biopsy with noncaseating granulomas confirms; biopsy is essential whenever findings suggest an alternative diagnosis such as lymphoma Slides 25, 44–45
Treatment/Therapy
About 90% respond to corticosteroids (indications: disabling constitutional symptoms, hypercalcemia, iritis, uveitis, arthritis, central nervous system or cardiac involvement, granulomatous hepatitis, skin lesions other than erythema nodosum, progressive pulmonary lesions); methotrexate, azathioprine or infliximab if intolerant or refractory; yearly exam, pulmonary function, chest film, electrocardiogram, chemistry and eye exam Slides 46–48
Mortality ★
Best with hilar adenopathy alone; parenchymal involvement is worse; 20% with lung involvement develop irreversible impairment (fibrosis, bronchiectasis, cavitation) Slide 48
Coal workers' pneumoconiosis1 not covered
Name of Condition
Coal workers' pneumoconiosis (a pneumoconiosis) Slides 50–51
Definition
Chronic fibrotic lung disease from inhaled coal dust Slide 50
Etiology (cause)
Inhaled coal dust taken up by alveolar macrophages, forming coal macules Slide 51
Epidemiology (who)
Not covered in the lecture
Risk Factors
Coal dust exposure Slide 50
Pathology
Coal macules; complicated disease is progressive massive fibrosis (conglomeration of the upper lungs) Slides 51, 54
Clinical Manifestation
Simple disease usually asymptomatic; complicated: progressive dyspnea, inspiratory crackles, clubbing, cyanosis Slide 52
Diagnosis
Restrictive pulmonary function with reduced diffusing capacity; chest film with nodular opacities in the upper lung fields (coal macules 2 to 5 mm) Slide 53
Treatment/Therapy
Supportive, no curative treatment: oxygen, pneumococcal and influenza vaccines, rehabilitation, smoking cessation; lung transplant in severe cases Slide 54
Mortality ★
Progressive massive fibrosis: conglomeration and contraction in the upper lung fields Slides 51, 54
Asbestosis (and mesothelioma)★ Professor emphasized

★ He said ferruginous bodies (which slide 55 ties to inorganic dust and significant exposure) should make you think asbestos; smoking markedly raises the lung cancer risk.

Name of Condition
Asbestosis Slide 55
Definition
Interstitial fibrosis of the terminal bronchioles, alveoli and interstitium from inhaled asbestos fibers that cannot be removed Slide 56
Etiology (cause)
Asbestos fibers from insulation, demolition, shipyards and construction Slide 55
Epidemiology (who)
Exposure over 10 to 20 years; patients usually seek attention about 15 years after exposure Slide 55
Risk Factors
Asbestos exposure; cigarette smoking increases radiographic changes and markedly increases lung carcinoma Slides 55–56
Pathology
Chronic inflammation and macrophage invasion form fibrosis; fibers can reach the pleura and cause mesothelioma; ★ ferruginous bodies in tissue suggest significant exposure Slides 55–56
Clinical Manifestation
Dyspnea on exertion, rarely cough; fine bibasilar crackles and clubbing with progression Slide 57
Diagnosis
Labs not helpful; reduced vital capacity and total lung capacity; imaging often normal early; pleural plaques the most common chest film finding, basal reticulonodular opacities; CT preferred (plaques, alveolitis, fibrosis, honeycombing) Slides 57–58
Treatment/Therapy
Supportive: oxygen, physiotherapy, medications, vaccinations Slide 56
Mortality ★
Increased lung cancer and mesothelioma, especially in smokers; mesothelioma (pleural, nearly always from asbestos, 10% lifetime risk in asbestos workers) is incurable with poor survival, diagnosed by pleural fluid cytology Slides 56, 59
Silicosis★ Professor emphasized1 not covered

★ A thick, milky lavage is "usually confirmatory"; screen for tuberculosis.

Name of Condition
Silicosis Slide 60
Definition
Fibrosis and nodular lung lesions from free crystalline silica dust (silicon dioxide) Slide 60
Etiology (cause)
Silica dust from mining, sandblasting, quarry work and stone work Slide 60
Epidemiology (who)
Not covered in the lecture
Risk Factors
Silica exposure Slide 60
Pathology
Silica deposits in the alveoli cause chronic inflammation, macrophage invasion, fibrosis and nodules, mostly in the upper lobes (a lighter dust); complicated disease conglomerates the upper lungs Slides 60, 63
Clinical Manifestation
Simple disease usually asymptomatic (slide 60); dyspnea, cough, weight loss, fatigue; crackles. Slide 61 also says "rapid onset of symptoms": the two slides differ on onset Slides 60–61
Diagnosis
Arterial blood gas; reduced forced vital capacity and forced expiratory volume in 1 second; ★ bronchoalveolar lavage: thick, milky effluent with foamy, lipoproteinaceous macrophages; silicotic nodules 1 to 10 mm and eggshell calcification of the hilar nodes Slides 62–63
Treatment/Therapy
Largely supportive: oxygen, physiotherapy, medications, vaccinations, smoking cessation; ★ tuberculosis skin test and a current chest film. (Slide 54, in the coal section, adds that corticosteroids may relieve the chronic alveolitis in silicosis) Slides 54, 64
Mortality ★
Increased risk of tuberculosis, progressive massive fibrosis, scleroderma Slide 64
Hypersensitivity pneumonitis★ Professor emphasized

★ "Find the agent, avoid the agent"; reversible if caught early.

Name of Condition
Hypersensitivity pneumonitis (extrinsic allergic alveolitis) Slide 65
Definition
A non-atopic, non-asthmatic inflammatory lung disease caused by inhaled organic material Slide 65
Etiology (cause)
Organic dusts: moldy hay (farmer's lung), bird excreta and feathers (bird fancier's lung), cheese maker's lung, moldy sugarcane pulp, insect-infested grain Slides 65, 67
Epidemiology (who)
Acute after exposure; subacute in 15% and chronic in 5%, after multiple exposures Slide 67
Risk Factors
Repeated exposure to the organic agent Slide 67
Pathology
Interstitial lymphocytes and plasma cells with noncaseating granulomas; fibrosis with continued exposure Slides 67, 70
Clinical Manifestation
Sudden malaise, chills, fever, cough, dyspnea, nausea 4 to 8 hours after exposure (may mimic paroxysmal nocturnal dyspnea); bibasilar crackles, tachypnea, tachycardia, cyanosis; chronic: fatigue, weight loss, fibrosis, clubbing Slides 66–68
Diagnosis
Serum antibodies to the agent (definitive); white count elevated with a left shift; hypoxia; restrictive function; little imaging change acutely, later small nodular densities sparing the apices and bases; biopsy if subacute or chronic Slides 69–70
Treatment/Therapy
★ Identify and avoid the agent; corticosteroids in severe cases; other immunosuppressants; oxygen, bronchodilators, pain medication; lung transplant Slide 71
Mortality ★
Symptoms can be reversible if caught early; continued exposure may worsen the disease Slide 65
Acute respiratory distress syndrome (ARDS)★ Professor emphasized

★ The most narration time of the lecture: a feared complication of sepsis, trauma, aspiration and more.

Name of Condition
Acute respiratory distress syndrome (ARDS) Slide 72
Definition
Acute non-cardiogenic lung injury: within 7 days of a known insult, bilateral opacities not explained by effusion, atelectasis or nodules, failure not fully explained by heart failure or fluid overload, arterial oxygen to inspired oxygen ratio under 300 mm Hg Slide 73
Etiology (cause)
Direct: aspiration of gastric contents, diffuse pneumonia, lung contusion, toxic gas, near-drowning, high altitude, radiation, upper airway obstruction, fat, air, amniotic fluid or thrombus emboli. Systemic: sepsis, severe pancreatitis, shock, nonthoracic trauma, overdoses (opioids, aspirin, phenothiazine, tricyclic antidepressants, cocaine), multiple transfusions, disseminated intravascular coagulation, cardiopulmonary bypass, protamine, chemotherapy, amiodarone, nitrofurantoin Slide 72
Epidemiology (who)
About one-third of cases first present with sepsis Slide 72
Risk Factors
The direct and systemic insults above Slide 72
Pathology
Cytokine damage to capillary endothelium and alveolar epithelium; increased permeability, surfactant loss, alveolar collapse and refractory hypoxemia; hyperinflammatory phenotype (high interleukin-6, soluble tumor necrosis factor receptor) with multiorgan failure Slides 72–73
Clinical Manifestation
Profound dyspnea 12 to 48 hours after the insult; tachypnea, labored breathing, intercostal retractions, crackles; hypoxemia refractory to supplemental oxygen; multiple organ failure Slide 73
Diagnosis
Bilateral infiltrates becoming confluent, air bronchograms in about 80%, normal heart size with few effusions; echocardiography excludes cardiogenic edema; severity by arterial oxygen to inspired oxygen ratio (mild 200 to 300, moderate 100 to 200, severe under 100 mm Hg); differential: cardiogenic edema, diffuse alveolar hemorrhage, severe bilateral pneumonia, autoimmune lung disease Slide 73
Treatment/Therapy
Treat the precipitant; low tidal volume ventilation; titrate positive end-expiratory pressure (arterial oxygen above 60 mm Hg); early prone positioning in moderate to severe disease; conservative fluids; transfuse at hemoglobin 7 g/dL; corticosteroids conditionally within 14 days; sedatives, analgesics, antipyretics; avoid oscillatory ventilation and routine pulmonary artery catheters; neuromuscular blockade controversial; extracorporeal membrane oxygenation as salvage Slide 74
Mortality ★
About 30% mortality with low tidal volume ventilation; 20% after trauma to 80% with end-stage liver disease; lung function improves over 6 to 12 months; residual diffusion deficits, weakness and fatigue Slides 72, 74

Lecture 42 · Pulmonary Vascular Disorders

Rob Gray, DMSc, PA-C (guest lecturer) · 7 conditions · source: Pulmonary Vascular Disorders 2026 - Gray.pptx

Note: Built from the slides plus the Zoom recording of the live lecture (he taught remotely), which only chooses which facts to star. Slides 3–62 are AI-made pictures with typing errors, read for meaning; the vital-sign monitors, graph numbers and gauge drawn on them are decoration, and the slide 3 admissions figure is left out. He said not to read the slide 20 stage charts, not to worry about the slide 24 wedge-pressure detail or the slide 28 critical rule (“this is ICU [intensive care unit] stuff”), that the endothelin receptor antagonists and prostacyclins are “for completeness” (known here by class), that slide 41 is a refresher, and not to memorize whole flowcharts (slides 57 and 61: the decision points are kept). No pressure threshold for pulmonary hypertension is on the slides and none is given. Points the slides state two ways are given both ways or not stated: “gold standard” (echo on slides 14 and 36, right heart catheterization on slide 24, computed tomography pulmonary angiography on slides 55 and 62; echo is given only as the initial or structural test), the wedge-pressure cut-off (15 mmHg for cor pulmonale against left heart failure on slides 4, 12 and 23; 18 to 20 for cardiogenic edema on slides 33, 38 and 45; each kept with its own question), nitrates (preload and afterload on slide 39, afterload on slide 46; slide 39 is kept), the slide 53 box label for a previous clot (only its points are given) and the slide 19 mechanism word for Group 3 (left out). Where he and a slide differ (what counts as malignancy in Wells; whether the Pulmonary Embolism Rule-out Criteria or Wells come first), the slide is kept. Said aloud but on no slide, and left out: sinus tachycardia as the usual electrocardiogram finding, the nitrate interaction with phosphodiesterase-5 inhibitors, calcium channel blocker names and the causes of a false-positive D-dimer; the slides name no anticoagulant or thrombolytic drug. Current guidelines differ on the jugular venous pressure reference (no number is given), the pneumococcal vaccines (valencies left out), routine morphine, mineralocorticoid receptor antagonists in preserved ejection fraction, the middle pulmonary embolism risk tier, the Wells and rule-out boundary wording and the non-surgical options for chronic thromboembolic disease; the slides are kept. Dosing is left out.
Cor pulmonale (acute and chronic)★ Professor emphasized

★ “COPD [chronic obstructive pulmonary disease] is the absolute leading cause”; “that alveolar hypoxia is the most important driver of that pulmonary hypertension when we get into our COPD patients”; “the visual hallmark of bad right heart pressure overload is that septal flattening … kind of turns the left ventricle into a D shape.”

Name of Condition
Cor pulmonale, acute and chronic Slides 4, 9
Definition
Alteration in the structure and function of the right ventricle (enlargement, hypertrophy or dilation) caused exclusively by a primary disorder of the respiratory system or pulmonary vasculature: an elevated mean pulmonary artery pressure with a normal pulmonary capillary wedge pressure. Right ventricular failure from left heart failure (Group 2 pulmonary hypertension) is NOT cor pulmonale. Acute: sudden right ventricular dilation and dysfunction over minutes to hours; chronic: concentric hypertrophy, then late dilation, over months to years Slides 4, 9, 18
Etiology (cause)
Parenchymal (primarily chronic): ★ chronic obstructive pulmonary disease, the absolute leading cause; interstitial lung disease (fibrotic destruction of lung architecture); sleep-disordered breathing (chronic nocturnal alveolar hypoventilation). Vascular (acute and chronic): acute pulmonary thromboembolism (sudden macroscopic occlusion); primary pulmonary arterial hypertension (idiopathic vascular remodeling, Group 1); chronic thromboembolic pulmonary hypertension (unresolved clot burden, Group 4). Acute cor pulmonale: massive pulmonary embolism. Chronic: chronic obstructive pulmonary disease, interstitial lung disease, pulmonary arterial hypertension Slides 5, 9
Epidemiology (who)
Present in more than 50% of patients with chronic obstructive pulmonary disease; left ventricular failure is still the most common cause of right ventricular failure overall Slides 5, 18
Risk Factors
The underlying lung or pulmonary vascular disease; global alveolar hypoxia and hypercapnia (the chronic obstructive pulmonary disease “Blue Bloater”); loss of the vascular bed (emphysema, fibrosis, embolism); polycythemia from chronic hypoxia, which raises blood viscosity Slides 6–7
Pathology
★ Alveolar hypoxia is the single most important driver of pulmonary hypertension in chronic obstructive pulmonary disease: global alveolar hypoxia and hypercapnia trigger diffuse, system-wide vasoconstriction (unlike the targeted reflex that shunts blood away from one hypoxic area), a massive rise in pulmonary vascular resistance and a relentless rise in right ventricular afterload. Vascular bed obliteration (emphysema, fibrosis, embolism) makes the resistance anatomical, not just functional, and polycythemia adds viscosity. The right ventricle is a thin-walled, high-compliance, low-pressure chamber, highly sensitive to sudden afterload changes. Acute: wall tension rises instantly (dilation, stretch, microinfarction), the septum bows leftward into the left ventricle, and left ventricular filling and output fall (hypotension, collapse). Chronic: compensatory hypertrophy until exhaustion, then decompensation, with raised diastolic pressures transmitted back into the systemic veins Slides 6–8, 10–11
Clinical Manifestation
Acute: severe sudden dyspnea, sweating, rapid pulse, pallor, syncope; distended neck veins, tricuspid regurgitation murmur (stretched annulus), tachycardia. Chronic: unproductive cough, progressive exertional dyspnea, the “Blue Bloater” phenotype; right ventricular heave (parasternal lift along the left sternal border), intensified P2, systolic murmur of tricuspid regurgitation; tender hepatomegaly, ascites, dependent peripheral pitting edema Slides 9–11
Diagnosis
Exclude elevated left-sided filling pressures first. A stepwise funnel: chest X-ray (interstitial markings or hyperinflation) and pulmonary function tests (obstructive: reduced forced expiratory volume in 1 second over forced vital capacity, the most common; restrictive: reduced total lung capacity) find lung disease (Group 3); a ventilation/perfusion scan or computed tomography pulmonary angiography excludes segmental defects (Group 4); right heart catheterization and echo showing a raised mean pulmonary artery pressure with a wedge pressure ≤15 mmHg leave primary vascular disease (Group 1). Chest film: flattened diaphragms (hyperinflation), enlarged central pulmonary arteries; the fields may look deceptively clear in pulmonary arterial hypertension or embolism. Electrocardiogram: peaked P waves (right atrial enlargement), tall R wave in V1 (right ventricular hypertrophy), severe right axis deviation in chronic disease; abnormal in 70% of acute pulmonary embolism. Echocardiography: right ventricular enlargement, estimated pulmonary artery systolic pressure and ★ systolic septal flattening, the D-shaped left ventricle Slides 4, 12–14
Treatment/Therapy
The prime directive: treat the underlying lung disease. Continuous supplemental oxygen in Group 3 (chronic obstructive pulmonary disease, interstitial lung disease): “oxygen is a drug” that reverses alveolar hypoxic vasoconstriction. Chronic obstructive pulmonary disease: bronchodilators and aggressive treatment of respiratory infections. Acute embolism: thrombolytics and anticoagulation (expand blood volume if hypotensive). Pulmonary arterial hypertension: targeted therapy (phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclins). Fluids: careful diuresis (loop diuretics, spironolactone) for retention, never aggressive: the damaged right ventricle relies on elevated preload, and over-diuresis starves the left ventricle Slides 15–16
Mortality ★
Acute: decreased left ventricular filling and immediate cardiovascular collapse (shock). Chronic: progressive volume overload, hypoxemia and right heart failure. Over-diuresis causes a disastrous drop in cardiac output; hypokalemia can trigger lethal arrhythmias Slides 9, 16
Pulmonary hypertension★ Professor emphasized1 not covered

★ “Right heart is gonna be your gold standard”; on the risk table, “When I start having signs of RV [right ventricular] failure, I’m automatically at high risk. I got higher than 10% chance of dying in the next year,” and for any three-column table, “remember the one in the middle”; “PDE5 [phosphodiesterase-5] inhibitors, you should know. That’s your AFILs” (sildenafil, tadalafil). The other two drug classes are “specialty sorcery … for completeness.”

Name of Condition
Pulmonary hypertension (World Health Organization Groups 1 to 5) Slide 19
Definition
Raised pressure in the pulmonary circulation that loads the right ventricle, classified by the World Health Organization by mechanism: pre-capillary Group 1 (pulmonary arterial hypertension; obliterative/proliferative), Group 3 (lung disease/hypoxia) and Group 4 (chronic thromboembolic; obstructive); post-capillary Group 2 (left heart disease; passive); Group 5 (unclear/multifactorial; complex) Slide 19
Etiology (cause)
Group 1: idiopathic, connective tissue disease, human immunodeficiency virus, schistosomiasis. Group 2: obstruction to pulmonary venous outflow (heart failure with reduced or preserved ejection fraction, mitral stenosis). Group 3: chronic obstructive pulmonary disease, interstitial lung disease, sleep apnea. Group 4: chronic thromboembolic occlusion. Group 5: hematologic, systemic and metabolic disorders (for example, sarcoidosis) Slide 19
Epidemiology (who)
Not covered in the lecture
Risk Factors
Chronic hypoxia (a potent pulmonary vasoconstrictor); chronic lung disease; previous pulmonary embolism (chronic thromboembolic disease); left heart disease Slides 19, 27
Pathology
Pressure destroys the pump in three stages: compensatory right ventricular hypertrophy against rising pulmonary vascular resistance; dilation and failure (the Starling mechanism fails, end-diastolic volume rises); ventricular interdependence (the dilated right ventricle bows the septum into the left ventricle), which impairs left ventricular diastolic filling and output and causes exertional syncope despite normal left ventricular contractility Slide 20
Clinical Manifestation
Exertional dyspnea and fatigue, often the only early symptom and frequently misattributed to deconditioning (World Health Organization class I to II); dizziness, lightheadedness and marked limitation of activity (class III); syncope or presyncope, an ominous sign of a fixed low cardiac output (class IV); end-stage abdominal bloating, early satiety and edema, present even at rest. Exam: elevated jugular venous pressure with large a waves (early) or regurgitant v waves (tricuspid insufficiency); parasternal lift (right ventricular heave); accentuated P2; right ventricular S3 gallop; hepatojugular reflux (sustained pressure on the liver raises the venous pressure by more than 1 cm); pitting edema to the hips and sacrum when severe; cool extremities; lungs typically clear, unlike the orthopnea, paroxysmal nocturnal dyspnea and crackles of left heart failure Slides 21–23
Diagnosis
Echocardiography is the most useful initial (screening) test: right ventricular size and function, pulmonary pressures and left-sided valvular or myocardial mimics. A ventilation/perfusion scan is essential to exclude chronic thromboembolic pulmonary hypertension (do not rely on computed tomography angiography alone). ★ Right heart catheterization is the mandatory confirmatory test: it directly measures mean pulmonary artery pressure, wedge pressure and pulmonary vascular resistance to confirm pre-capillary pulmonary hypertension (a normal or low wedge ≤15 mmHg with a raised mean pulmonary artery pressure; above 15 mmHg points to left heart failure). Chest film: enlarged central pulmonary arteries with peripheral pruning Slides 23–24
Treatment/Therapy
Careful diuresis (intravenous loop diuretics venodilate before they diurese; avoid aggressive over-diuresis, which drops preload and crashes output); oxygen to keep PaO2 (arterial oxygen pressure) above 60 mmHg, especially during sleep or exertion; avoid strict bedrest: supervised, steady aerobic rehabilitation; annual influenza and pneumococcal immunizations. Drug classes: endothelin receptor antagonists (ambrisentan, bosentan, macitentan), ★ phosphodiesterase-5 inhibitors (sildenafil, tadalafil), prostacyclins (epoprostenol, treprostinil, iloprost, selexipag; the most potent vasodilators, essential for severe disease). Vasoreactive: high-dose oral calcium channel blockers. Not vasoreactive: low or intermediate risk (class II/III) = oral combination therapy (endothelin receptor antagonist plus phosphodiesterase-5 inhibitor; early combination beats sequential monotherapy); high risk (class IV or rapid decline) = continuous intravenous or subcutaneous prostanoids (epoprostenol). Refractory disease (or pulmonary veno-occlusive disease): lung transplantation, the only definitive option, with intravenous support as a bridge. Early palliative care discussions and advance directives Slides 26–29
Mortality ★
Estimated 1-year mortality by risk: low (<5%: no right ventricular failure signs, slow progression, no syncope, class I or II, 6-minute walk >440 m); intermediate (5 to 10%: no right ventricular failure signs, moderate progression, occasional syncope, class III, 165 to 440 m); high (>10%: ★ clinical signs of right ventricular failure present, rapid progression, repeated syncope, class IV, <165 m). Sudden death or lethal syncope can be the first sign of progression; 6% survival at 90 days after cardiopulmonary resuscitation in pulmonary arterial hypertension Slides 25, 29
Pulmonary edema (cardiogenic)★ Professor emphasized

★ “Over 18 to 20 is cardiogenic type failure” (the wedge pressure). His first question in any edema: “pipes, pumps, or filter? … your differentials all spring from the answer to that question.” Pink frothy sputum is “a big sign, but it’s late in the game”; LMNOP is “like my toolbox, not a checklist.”

Name of Condition
Cardiogenic pulmonary edema (the pressure problem) Slide 33
Definition
Fluid flooding the alveolar airspace when the outward capillary hydrostatic pressure exceeds the inward plasma oncotic pressure across an intact but overwhelmed capillary membrane: the pressure problem, “the pump is failing,” with ★ a wedge pressure above 18 to 20 mmHg Slides 32–33, 38
Etiology (cause)
Systolic dysfunction (ischemic loss of functioning myocardium; heart failure with reduced ejection fraction); diastolic dysfunction (myocardial stiffening and aging; heart failure with preserved ejection fraction); valvular lesions (chronic aortic or mitral regurgitation, severe stenosis) Slide 34
Epidemiology (who)
Adults: usually ischemia-driven loss of pump function (reduced ejection fraction). The elderly: age-related myocardial stiffening (preserved ejection fraction) Slide 42
Risk Factors
Heart failure (reduced or preserved ejection fraction), myocardial ischemia, valvular disease; flash edema triggers: acute myocardial infarction, severe ischemia, severe hypertension, and in chronic heart failure nonadherence, excess salt or rapid arrhythmias Slides 34, 46
Pathology
Elevated capillary hydrostatic pressure is the engine; plasma oncotic pressure is the failing counterbalance; the semipermeable membrane stays intact but is overwhelmed, so fluid floods the alveoli. The balloon-wedged catheter “looks forward” through the capillary bed to the left atrial pressure. The elderly heart (preserved ejection fraction) has an elevated end-diastolic pressure, extreme sensitivity to preload and a narrow therapeutic margin Slides 32, 38, 42
Clinical Manifestation
Acute dyspnea, diaphoresis and tripoding (catecholamine surge, extreme work of breathing); bilateral rales/crackles and wheezing (fluid-filled airways, peribronchial cuffing); S3 gallop (an overloaded, failing ventricle); pink, frothy sputum (alveolar fluid shift with microvascular hemorrhage) Slide 35
Diagnosis
B-type natriuretic peptide (or N-terminal pro-B-type natriuretic peptide) proves ventricular stretch and volume overload; substantial elevation separates cardiogenic dyspnea from pulmonary mimics. Transthoracic echo: the best test for structure (ventricular size, ejection fraction, valves). Pulmonary artery catheter/right heart catheterization: the ultimate hemodynamic arbiter when the cause is uncertain (★ wedge above 18 to 20 mmHg confirms cardiogenic hydrostatic failure). Chest X-ray: batwing (central perihilar) opacities, peribronchial cuffing, Kerley B lines (fluid in the interlobular septa), bilateral pleural effusions. Mimics share dyspnea, hypoxemia and tachycardia: heart failure has a highly elevated natriuretic peptide, echo abnormalities and Kerley B lines; pulmonary embolism has clear lungs, a normal natriuretic peptide initially and S1Q3T3 or right ventricular strain; a chronic obstructive pulmonary disease exacerbation has wheezing or hyperinflation, hypercapnia and a usually normal natriuretic peptide Slides 36–38, 43
Treatment/Therapy
LMNOP: Loop diuretics intravenously (furosemide, bumetanide, torsemide) for rapid volume reduction; Morphine only with caution (venodilation and anxiolysis against respiratory depression); Nitrates intravenously (immediate preload and afterload reduction by venodilation, lowering capillary hydrostatic pressure); Oxygen and upright positioning (gravity drops venous return); Positive airway pressure (noninvasive ventilation stents alveoli, pushes fluid back and lowers preload and afterload). Long term: quadruple therapy (angiotensin receptor-neprilysin inhibitor such as sacubitril-valsartan, beta-blockers, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors). Adults (reduced ejection fraction) generally tolerate aggressive diuresis; the elderly (preserved ejection fraction) need gentle, precise diuresis. Stage D: immediate evaluation for heart transplant, mechanical circulatory support (left ventricular assist device) or palliative hospice care Slides 39–42, 44
Mortality ★
Quadruple therapy gives the greatest mortality reduction in reduced ejection fraction. Elderly: over-diuresis causes precipitous hypotension, under-diuresis recurrent drowning. Stage D (marked symptoms at rest despite maximal medical therapy, frequent hospitalizations) is the break point that triggers referral for advanced therapies Slides 41–42, 44
Noncardiogenic pulmonary edema5 not covered
Name of Condition
Noncardiogenic pulmonary edema (the permeability problem) Slide 33
Definition
Pulmonary edema from a shattered capillary endothelium leaking protein-rich fluid: the permeability problem, “the pipe is leaking,” with a wedge pressure ≤18 mmHg (normal or low) Slides 33, 46
Etiology (cause)
Acute respiratory distress syndrome (severe inflammatory capillary destruction); sepsis (systemic vasodilation and endothelial leak); toxins (inhaled chemical injury to the alveolar-capillary membrane); high altitude Slides 34, 46
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
The barrier itself shatters: protein-rich fluid floods the alveolar airspace without a hydrostatic backup; underlying cardiac function is typically normal Slides 32–33, 46
Clinical Manifestation
Not covered in the lecture
Diagnosis
A normal or low wedge pressure (≤18 mmHg) separates it from cardiogenic edema, in which cardiac enlargement or dysfunction is common. A pulmonary artery catheter/right heart catheterization measures the left-sided filling pressures when the cause is uncertain Slides 33, 36, 46
Treatment/Therapy
Not covered in the lecture
Mortality ★
Not covered in the lecture
Flash pulmonary edema2 not covered
Name of Condition
Flash pulmonary edema Slide 46
Definition
Pulmonary edema presenting as an acute emergency (severe dyspnea, pink frothy sputum); cardiogenic forms have an elevated wedge pressure, noncardiac forms a normal or low one Slide 46
Etiology (cause)
Underlying cardiac causes: acute myocardial infarction, severe ischemia or severe hypertension. Chronic heart failure exacerbations: nonadherence, excess salt or rapid arrhythmias. Noncardiac causes (acute respiratory distress syndrome, high altitude, sepsis, toxins) are told apart by a normal wedge pressure Slide 46
Epidemiology (who)
Not covered in the lecture
Risk Factors
Chronic heart failure with nonadherence, excess salt or rapid arrhythmias; acute myocardial infarction, severe ischemia, severe hypertension Slide 46
Pathology
Cardiogenic: elevated wedge pressure, cardiac enlargement or dysfunction common. Noncardiac: normal or low wedge pressure, underlying cardiac function typically normal Slide 46
Clinical Manifestation
Severe dyspnea, cyanosis, diaphoresis and pink frothy sputum; diffuse bilateral rales, rhonchi and expiratory wheezing Slide 46
Diagnosis
Chest X-ray: butterfly pattern edema and vascular blurring. Elevated B-type natriuretic peptide, elevated wedge pressure, hypoxemia; a normal or low wedge pressure points to a noncardiac cause Slide 46
Treatment/Therapy
Sit the patient upright with legs dangling over the bed; oxygen or noninvasive ventilation; intravenous furosemide (immediate venodilation and diuresis); intravenous nitrates. Temporarily hold outpatient therapy during acute kidney injury; continue oral beta-blockers unless the patient presents in shock; morphine only cautiously (it eases anxiety but risks severe ventilatory drive reduction) Slide 46
Mortality ★
Not covered in the lecture
Pulmonary embolism (PE)★ Professor emphasized1 not covered

★ His top point: “Don’t rely on shortness of breath … about a quarter of people with, like, giant PEs [pulmonary embolisms] don’t have dyspnea … If you walk away with nothing else from this lecture today, y’all, walk away with that.” S1Q3T3 is “a board question” and the chest-film signs are “great for board questions”; Wells and PERC [Pulmonary Embolism Rule-out Criteria] are his “big two tools” (Wells first; in Lecture 44: “that’s fair game”); on the risk tiers, “know the one in the middle, and you’re good”; computed tomography pulmonary angiography is “your gold standard,” with a ventilation/perfusion scan when it cannot be used; echo “is not for diagnosis, it’s for stratification”; thrombolysis: “We don’t really like doing it for submassive.”

Name of Condition
Pulmonary embolism (PE), part of venous thromboembolism Slide 48
Definition
Sudden macroscopic occlusion of the pulmonary vasculature by thromboembolism. Deep venous thrombosis and pulmonary embolism are one continuum of the same disease (venous thromboembolism), ranging from asymptomatic disease to hemodynamic collapse and death; massive embolism causes acute cor pulmonale Slides 5, 9, 48
Etiology (cause)
Thrombosis driven by Virchow’s triad (hypercoagulability, venous stasis, endothelial injury); the clot of deep venous thrombosis and of pulmonary embolism is one process Slides 48–49
Epidemiology (who)
Not covered in the lecture
Risk Factors
Hypercoagulability: malignancy, estrogen therapy, pregnancy, genetic thrombophilias, sepsis. Venous stasis: prolonged immobilization (flights over 8 hours), bed rest, paralysis, heart failure (New York Heart Association class III/IV). Endothelial injury: recent surgery, central venous catheters, pacemaker wires, pelvic or lower limb trauma. Not finding a known predisposition should never stop an objective evaluation when the presentation fits Slide 49
Pathology
Massive embolism causes acute right ventricular pressure overload; the septum bows into the left ventricle, left ventricular end-diastolic volume and filling fall, and cardiac output crashes (circulatory collapse). Distal, pleural-based occlusion causes pulmonary infarction Slides 50, 56
Clinical Manifestation
Three syndromes: isolated dyspnea (sudden, over minutes to hours, at rest or only with exertion); pleuritic pain and hemoptysis (distal pleural-based infarction, often a localized friction rub); circulatory collapse (syncope, severe hypotension, obstructive shock = massive proximal occlusion). ★ The dyspnea trap: about 25% of patients with proven pulmonary embolism completely lack dyspnea. Massive embolism (acute cor pulmonale): distended neck veins, tricuspid regurgitation murmur, tachycardia, pallor Slides 10, 50, 62
Diagnosis
Bayesian: the pre-test probability, set independently of any test, chooses the test and how to read it. ★ Wells score: +3 signs and symptoms of deep venous thrombosis; +3 pulmonary embolism the leading diagnosis; +1.5 heart rate >100; +1.5 immobilization >3 days or surgery in the previous 4 weeks; +1.5 previous deep venous thrombosis or pulmonary embolism; +1 hemoptysis; +1 malignancy (on treatment, treated in the last 6 months, or palliative); ≤4 = unlikely, >4 = likely. Unlikely: ★ the Pulmonary Embolism Rule-out Criteria (very low gestalt, <15%): age <50, heart rate <100, oxygen saturation >94%, no hemoptysis, no exogenous estrogen, no prior venous thromboembolism, no surgery or trauma, no unilateral leg swelling; all true = stop the workup; any failed = a highly sensitive D-dimer (a negative enzyme-linked immunosorbent assay D-dimer safely excludes; positive = computed tomography pulmonary angiography). Both are outpatient rule-out tools; the D-dimer is of limited use in inpatients (universally high false positives). Likely: skip the D-dimer and go straight to ★ computed tomography pulmonary angiography, the gold standard (first-line for almost all; contrast, radiation, overdiagnosis of subsegmental emboli), or a ventilation/perfusion scan if contrast is contraindicated (renal dysfunction, severe contrast allergy, critically ill; often nondiagnostic with chronic obstructive pulmonary disease or severe heart failure; a completely negative scan excludes embolism as surely as a negative pulmonary angiogram). Electrocardiogram: ★ S1Q3T3 (deep S wave in lead I, Q wave and inverted T wave in lead III) suggests severe right ventricular strain, not purely embolism; highly specific, low sensitivity. Chest film: usually abnormal but nonspecific (atelectasis, effusion); ★ classic signs Westermark (focal peripheral oligemia), Hampton’s hump (wedge-shaped pleural-based opacity, infarction) and Palla (enlarged right descending pulmonary artery) are highly suggestive but infrequent. ★ Transthoracic echo has poor sensitivity (about 50%) but very high specificity for right ventricular strain (the D-shaped septum): risk stratification, not diagnosis Slides 51–57
Treatment/Therapy
Stratify: low risk (normotensive, no right ventricular dysfunction, negative biomarkers) = standard anticoagulation; ★ submassive/intermediate risk (normotensive, systolic >90, but right ventricular dysfunction on echo or computed tomography pulmonary angiography, or myocardial necrosis with raised troponin or B-type natriuretic peptide) = high risk of sudden deterioration; massive/high risk (sustained hypotension with systolic <90 for more than 15 minutes, pulselessness or profound bradycardia) = immediate advanced intervention. Anticoagulate all, immediately on diagnosis or on high suspicion while awaiting imaging (halts propagation, allows endogenous fibrinolysis; the same principles as deep venous thrombosis); provoked (recent surgery, trauma, hospitalization, estrogen therapy) = consider stopping after 3 months; unprovoked or persistent (active malignancy, hypercoagulable states, no identifiable risk factor) = indefinite. Massive (unstable): systemic or catheter-directed thrombolysis; with absolute contraindications to thrombolytics (recent surgery, active bleeding) or a right heart clot in transit: mechanical thrombectomy or surgical embolectomy. Submassive: thrombolysis highly controversial (major bleeding, intracranial hemorrhage). Screen for chronic thromboembolic pulmonary hypertension if dyspnea persists at 3 months Slides 58–62
Mortality ★
Massive: high mortality; submassive: high risk of sudden deterioration; low risk: excellent prognosis. The long tail is chronic thromboembolic pulmonary hypertension Slides 58, 61
Chronic thromboembolic pulmonary hypertension (CTEPH)★ Professor emphasized2 not covered

★ “The optimal management for CTEPH is surgical. They’re gonna go in … and, like, pull out the clots.” On the ventilation/perfusion pearl: “CTA [computed tomography angiography] is great, but sometimes CTA is gonna miss some really subtle findings … this patient may end up being, like, a surgical candidate.”

Name of Condition
Chronic thromboembolic pulmonary hypertension (CTEPH), World Health Organization Group 4 Slide 61
Definition
Pulmonary hypertension from unresolved clot burden (chronic thromboembolic occlusion): a pre-capillary, obstructive mechanism, Group 4; the long tail of pulmonary embolism Slides 5, 19, 61
Etiology (cause)
Unresolved clot burden after pulmonary embolism (chronic thromboembolic occlusion) Slides 5, 19
Epidemiology (who)
Not covered in the lecture
Risk Factors
Unprovoked pulmonary embolism; delay in diagnosis of more than 2 weeks; right ventricular dysfunction on the initial computed tomography pulmonary angiogram; recurrent pulmonary embolism Slide 61
Pathology
Pre-capillary, obstructive: chronic thromboembolic occlusion of the pulmonary vascular bed Slide 19
Clinical Manifestation
Persistent or worsening dyspnea after 3 months of anticoagulation for pulmonary embolism Slide 61
Diagnosis
Screen for persistent or worsening dyspnea after 3 months of anticoagulation. No dyspnea: decide the length of anticoagulation by the risk of recurrent venous thromboembolism. Persistent dyspnea: ventilation/perfusion scan (normal perfusion: back to the length decision; abnormal perfusion: transthoracic echo, right heart catheterization and pulmonary angiogram, then referral to an expert center for chronic thromboembolic disease). ★ The ventilation/perfusion scan is the essential test to exclude it: do not rely on computed tomography angiography alone, because a high-probability mismatch leads to a surgical pathway. In the cor pulmonale funnel, segmental defects on a ventilation/perfusion scan or computed tomography pulmonary angiography mark thromboembolic disease (Group 4) Slides 12, 24, 61
Treatment/Therapy
Continue anticoagulation during the workup; refer to an expert center; ★ the optimal management is surgical: pulmonary thromboendarterectomy Slides 24, 61
Mortality ★
Not covered in the lecture

Lecture 43 · Pulmonary Nodules and Neoplasms

Rob Gray, DMSc, PA-C (guest lecturer) · 10 conditions · source: Pulmonary Nodules and Neoplasms 2026.pptx

Note: Built from the slides plus the Zoom recording of the live lecture, which only chooses which facts to star; slide 49 (“Things to Know”) is his own exam list. He said not to memorize the Fleischner tables, the probability-of-malignancy tables, the staging charts in detail, the genes, drugs by marker or the small cell follow-up schedule, so those are summarized or left out. Points the slides state two ways are given both ways or not stated: adenocarcinoma’s share (slides 4 and 31 give different percentages; it is kept as the most common type), stage 3 treatment (slide 35’s text against its table), immunotherapy for squamous cell (slides 37 and 38 against slide 40), the slide 46 “central” and “peripheral” tags on the neurologic syndromes (slide 47 places Lambert-Eaton at the neuromuscular junction), pleural contact as a benign sign (slide 16 against slide 32) and where most lung cancers form (slide 9 against slide 30). The slide 35 survival-by-stage column (never narrated) and dosing are left out. Current guidelines screen younger patients with fewer pack-years than slide 18; the slide’s criteria are kept. The slides give carcinoid tumors, the syndrome of inappropriate antidiuretic hormone and hypercalcemia no workup or treatment, and none is added.
Pulmonary nodule★ Professor emphasized

★ “Magic number is 6. Greater than 6 millimeters, I’m suspicious … Especially if I’ve got a spiculated appearance”; a benign nodule’s look, what makes a nodule worrying and the screening criteria are on his slide 49 exam list.

Name of Condition
Pulmonary nodule (a solitary nodule on a chest X-ray is a coin lesion) Slide 12
Definition
A nodule seen on a chest X-ray or chest computed tomography; a solitary nodule on a chest X-ray is sometimes called a coin lesion. Most are benign, but some are the start of a cancer Slides 4, 12
Etiology (cause)
Most are benign: a granuloma (inflammatory) or a hamartoma (connective tissue growth); some are the start of lung cancer Slides 4, 12
Epidemiology (who)
Found incidentally when a chest X-ray or chest computed tomography is done for another reason; most are benign Slide 12
Risk Factors
For malignancy: a patient at high risk of lung cancer (smoking is implicated in 85 to 90% of lung cancers), whose nodule is worked up to exclude malignancy Slides 3, 12, 16
Pathology
Concerning: ★ greater than 6 mm, upper lobes or hilar structures, ★ spiculated (spikes, deviations or lobulations in the border), more than 3 nodules, enlarging over time, contrast enhancing on computed tomography, cavitated or nonsolid, a patient at high risk; ground-glass (stippled) or eccentric calcification. Benign: well-defined borders, fat (hamartoma), diffuse, central, popcorn (hamartoma) or concentric calcification, close to a fissure. On computed tomography: a smooth nodule with fat and calcification (hamartoma), a smooth nodule with central calcification (healed granuloma), an opacity beside the minor fissure (linear scar or lymphoid tissue) Slides 16, 21
Clinical Manifestation
Usually none: an incidental finding. Persistent cough, hemoptysis, dysphagia, wheezing or shortness of breath, or systemic symptoms (weight loss, fever or fatigue, bone or chest pain, endocrine disorders) call for a lung cancer workup instead Slide 12
Diagnosis
First estimate the size (under 6 mm is generally not concerning unless the patient is high risk). Chest X-ray is not a good tool beyond first spotting it; computed tomography with contrast of the chest and upper abdomen, then biopsy (bronchoscopy, transthoracic or thoracoscopic, by location; can be guided by computed tomography); positron emission tomography (high uptake suggests malignancy, low or normal uptake is a good sign, inflammation can also take it up). A new solid nodule of 8 to 30 mm: assess the clinical probability of malignancy. Screening, for high-risk people without symptoms or a known nodule: ★ ages 55 to 80, at least a 30 pack-year history, smoking now or quit within the last 15 years, with a low-dose chest computed tomography every year. The Fleischner Society tables (2017) guide follow-up of incidental nodules (he said not to memorize them) Slides 11–12, 14, 16–19
Treatment/Therapy
By the probability of malignancy (new solid nodule of 8 to 30 mm): very low, computed tomography surveillance at 3 to 6, 9 to 12 and 18 to 24 months; low to moderate, positron emission tomography (negative or mild uptake: the same surveillance; moderate or intense uptake: nonsurgical biopsy or video-assisted thoracoscopic surgery with resection); high, staging, then video-assisted thoracoscopic surgery with resection if no metastases are found. Refer (pulmonologist, thoracic surgeon, interventional radiologist or oncologist) for a high probability or moderate to intense uptake. A single solid nodule under 6 mm in a low-risk patient needs no routine follow-up Slides 11, 19
Mortality ★
Most nodules are benign. Screening finds cancer early (rapid intervention, better prognosis) but has many false positives that lead to unnecessary workups with complications such as a biopsy Slides 12, 18
Lung cancer (bronchogenic carcinoma)★ Professor emphasized

★ His slide 49 list covers screening, staging and how it changes treatment, central versus peripheral types and the paraneoplastic signs. “By the time you get symptoms, we’re way late in the game”: in a patient with chronic obstructive pulmonary disease the symptoms can pass for an exacerbation.

Name of Condition
Lung cancer (bronchogenic carcinoma): small cell and non-small cell lung carcinoma Slide 4
Definition
Malignancies arising from the lung’s epithelial cells. Two main types: small cell lung carcinoma (oat cell) and non-small cell lung carcinoma (adenocarcinoma, squamous cell carcinoma, large cell carcinoma); mixed and rare types include carcinoid tumors, bronchial gland carcinoma, sarcomatoid carcinoma and Pancoast tumors Slide 4
Etiology (cause)
Carcinogens (or other causes of genetic mutation) activate oncogenes, and further mutations or loss of regulatory control inactivate tumor-suppressing genes; smoking is implicated in 85 to 90% of cases (second-hand smoke 20%) Slides 3, 9
Epidemiology (who)
More than 200,000 new cases a year in the United States and 2 million worldwide; most occur over 50 years old, but ★ about 4% under 40, so it stays on the differential. Small cell is 15 to 20% of lung cancers; adenocarcinoma is the most common type, squamous cell 20 to 30%, large cell 9 to 10% Slides 3–4, 31
Risk Factors
Smoking (85 to 90% of cases; second-hand smoke 20%), the risk compounding with packs per day and years (5x to 10x to 20x); radiation and radon; air pollution; environmental and chemical toxins; tuberculosis or human immunodeficiency virus infection; genetics; diet; alcohol intake Slide 3
Pathology
Atypical epithelial cells proliferate and grow into the bronchial lumen, along the mucosa or into the bronchial wall and parenchyma: hyperplasia, dysplasia, in situ cancer, invasive malignancy entering blood and lymph, then metastases. Spread is to regional lymph nodes and distant organs (liver, brain, bone) through angiogenesis and loss of differentiation. ★ Small cell and squamous cell are central; adenocarcinoma and large cell are peripheral. Neuroendocrine cells lining the bronchioles are where the paraneoplastic syndromes start Slides 6, 9–10, 30
Clinical Manifestation
★ Often no symptoms until the disease is advanced or metastatic. Persistent cough, hemoptysis, dysphagia, wheezing or shortness of breath; weight loss, fever or fatigue, bone or chest pain, endocrine disorders. Metastases with no respiratory symptoms: brain (headaches, vision changes, nausea, vomiting, syncope, seizures; papilledema with raised intracranial pressure; cranial nerve findings near the midbrain or pons), liver (dull right upper quadrant ache, firm hepatomegaly, poor appetite, jaundice, hepatic failure), bone (pain, fractures without falls, even from a cough; spinal cord compression), adrenal insufficiency (fatigue, weight loss, dizziness, hypotension, hyponatremia with hyperkalemia). Paraneoplastic: endocrine (syndrome of inappropriate antidiuretic hormone, hypercalcemia), neurologic (Lambert-Eaton myasthenic syndrome, with progressive weakness particularly in the legs; cerebellar degeneration or encephalitis), dermatologic (acanthosis nigricans, dermatomyositis), hematologic Slides 12–13, 46–47
Diagnosis
Screening (no symptoms, no known nodule): ★ ages 55 to 80, at least a 30 pack-year history, smoking now or quit within the last 15 years: a low-dose chest computed tomography every year. Workup: chest X-ray is not a good tool; computed tomography with contrast of the chest and upper abdomen, then biopsy (bronchoscopy, transthoracic or thoracoscopic); positron emission tomography; genetic testing; complete blood count with differential, comprehensive metabolic panel including calcium, alkaline phosphatase, pulmonary function tests; sputum cytology (not sensitive). Staged once computed tomography (location and size), positron emission tomography (lymph involvement) and biopsy (tumor type) are back, by tumor, node and metastasis: ★ a bigger tumor, nodes further away and metastasis are each worse; mediastinal or contralateral nodes (N2 or N3) make it stage 3; spread to the other lung, the pleura or pericardium, or outside the chest makes it stage 4 (4A one site outside the chest, 4B several) Slides 14, 18, 22–29
Treatment/Therapy
Non-small cell: ★ stages 1 to 2 surgical resection if the patient can tolerate it; stage 4 chemotherapy. Small cell: ★ chemotherapy and radiation, to which it responds better than the non-small cell types, with prophylactic cranial irradiation. Unfit for surgery: radiotherapy or ablation. Referral to a pulmonologist, thoracic surgeon, interventional radiologist or oncologist Slides 11, 15, 35, 41, 43
Mortality ★
The highest cancer mortality in men (more than 30% of male cancer deaths) and more than 25% of female cancer deaths; one of the lowest five-year survivals, 17 to 18% in the United States (worse in the rest of the world), because symptoms come only once it is advanced or metastatic Slides 3, 12
Non-small cell lung cancer (NSCLC)★ Professor emphasized1 not covered

★ On his slide 49 list: how staging changes treatment, big picture only (“do we do surgery? Do we do chemo? … Do you need to know every circumstance? No. Like, big picture, guys”). He said not to learn specific drugs by marker: “Your job as a primary care PA … is be able to screen and figure out risk for that patient, and then refer.”

Name of Condition
Non-small cell lung cancer (NSCLC): adenocarcinoma, squamous cell carcinoma, large cell carcinoma Slide 4
Definition
The non-small cell lung carcinomas, divided by histology into adenocarcinoma, squamous cell carcinoma and large cell carcinoma Slide 4
Etiology (cause)
As for lung cancer: oncogenes activated and tumor-suppressing genes inactivated; molecular and genomic testing of the tumor looks for specific mutations and proteins (for example TP53, tumor protein 53, a tumor-suppressor gene that lets cancer grow when damaged) Slides 9, 36
Epidemiology (who)
Adenocarcinoma is the most common lung cancer, squamous cell 20 to 30% and large cell 9 to 10%; usually over 50 with a smoking history Slides 4, 31, 39
Risk Factors
Smoking (the strongest association is squamous cell; adenocarcinoma occurs without it too); the general lung cancer risk factors Slides 3, 31, 39
Pathology
★ Adenocarcinoma and large cell carcinoma are peripheral; squamous cell carcinoma is central, often arising in a bronchus; mixed types exist (adenosquamous) Slide 30
Clinical Manifestation
Respiratory symptoms first (cough, shortness of breath, chest tightness or pain, hemoptysis, fatigue); later bone pain, weight loss and paraneoplastic issues Slides 31, 39
Diagnosis
Computed tomography, positron emission tomography and biopsy with histology, then tumor, node and metastasis staging; a mucicarmine stain shows mucin in adenocarcinoma (negative may point to large cell); sputum cytology can catch squamous cell; tumor genetic testing helps the oncologist tailor therapy Slides 22, 30, 32, 36
Treatment/Therapy
Surgical resection by size and lymph involvement (wedge or segment resection, lobectomy, pneumonectomy; open or thoracoscopic) if the patient can tolerate it (survive and recover). ★ Stages 1 to 2: surgical resection; stage 4: chemotherapy, with surgery only for a solitary metastasis with a resectable primary (for stage 3 the slide’s text and its table differ). Chemotherapy and radiation are adjuncts, or for stage 4, because non-small cell cancers respond poorly to them; chemotherapy and immunotherapy can be targeted to genetic and protein markers (gene-marker targeted therapy is for non-squamous disease); checkpoint-inhibitor monoclonal antibodies (the “-mab” drugs) for some patients by marker, by response to standard treatment, or when not a surgical candidate. Unfit for lobectomy: anatomical segmentectomy; unfit for surgery: stereotactic ablative radiotherapy, radiofrequency ablation or conventional radical radiotherapy Slides 15, 35, 37–38
Mortality ★
Not covered in the lecture
Adenocarcinoma of the lung★ Professor emphasized

★ His board pointer, said three times: “Adenocarcinoma, large cell, usually periphery”; he circled the peripheral spiculated nodule on slide 32.

Name of Condition
Adenocarcinoma of the lung (a non-small cell lung cancer) Slide 31
Definition
A non-small cell carcinoma usually arising from type II pneumocytes by way of atypical adenomatous hyperplasia; described as noninvasive, minimally invasive or invasive Slides 31–32
Etiology (cause)
Type II pneumocytes (the cuboidal cells that secrete surfactant) are usually the origin, starting as atypical adenomatous hyperplasia Slides 8, 32
Epidemiology (who)
The most common lung cancer; usually over 50 with a smoking history, but smoking is not always associated Slides 4, 31
Risk Factors
Smoking (not always present); frequently associated with peripheral scars Slide 31
Pathology
★ Mid-lung and periphery. Grows in situ first, then by lepidic growth along the alveolar lining or by invading the stroma (minimally invasive); later it may invade the pleura and vessels or form its own vasculature (invasive). Initial metastases are to the lymphatics before it leaves the lungs; a mucicarmine stain shows its mucin Slides 30–32
Clinical Manifestation
Mostly asymptomatic early; persistent cough and shortness of breath without signs of infection; respiratory symptoms first (cough, shortness of breath, chest tightness or pain, hemoptysis, fatigue); later bone pain, weight loss and systemic (paraneoplastic) issues Slide 31
Diagnosis
Computed tomography: a peripheral spiculated nodule (on slide 32 it involved the pleura and proved an invasive adenocarcinoma); histology with a positive mucicarmine stain (mucin) Slide 32
Treatment/Therapy
As for non-small cell lung cancer: surgical resection for stages 1 to 2, chemotherapy for stage 4; targeted therapy and immunotherapy by genetic and protein markers Slides 35, 37
Mortality ★
Two-thirds present only with advanced disease (T2 or higher with N1 to N3 nodes) or metastatic disease Slide 31
Large cell carcinoma★ Professor emphasized3 not covered

★ “Large cell tends to met to the gut. Small intestine, bowel … that’s specific to large cell, so I would say stuff that, like, is unique to a thing makes a great test question.”

Name of Condition
Large cell carcinoma of the lung (a non-small cell lung cancer) Slide 33
Definition
A non-small cell carcinoma of exclusion: no specific genetic or histology markers; anaplastic, undifferentiated and pleomorphic, with cells about 3 times larger than baseline Slide 33
Etiology (cause)
Not covered in the lecture
Epidemiology (who)
9 to 10% of lung cancers Slide 4
Risk Factors
Not covered in the lecture
Pathology
Anaplastic, undifferentiated, pleomorphic cells about 3 times larger than baseline (kept apart from small cell because their treatments differ); subtypes giant-cell (sarcomatoid), basaloid, rhabdoid and neuroendocrine; ★ forms in the periphery; necrosis and hemorrhage more readily than other non-small cell types; angiogenesis (its own blood supply) Slides 30, 33–34
Clinical Manifestation
Metastasis to rare sites such as ★ the small intestine and bowel Slide 33
Diagnosis
Computed tomography: a large, cavitated mass, typically peripheral (unlike the central squamous cell carcinoma), with angiogenesis; biopsy with histology must still confirm it (a large amount of anaplastic tissue); a negative mucicarmine stain may point to it Slides 32–34
Treatment/Therapy
No standardized treatment, because of its variety and rarity Slide 33
Mortality ★
Not covered in the lecture
Squamous cell carcinoma of the lung★ Professor emphasized1 not covered

★ On his slide 49 list (“how to recognize squamous cell from the others”): “Cavitation is big with that one. Strongest association with smoking … Cough, wheezing, hemoptysis are huge”; it can look like a chronic obstructive pulmonary disease patient “constantly in exacerbation”; “your squamous cell will make your calcium, a big deal.”

Name of Condition
Squamous cell carcinoma of the lung (a non-small cell lung cancer) Slide 39
Definition
A non-small cell carcinoma in a central location, often originating in the bronchus, with frequent cavitation and obstructive phenomena Slide 39
Etiology (cause)
Smoking: its association is the strongest of any lung cancer type Slide 39
Epidemiology (who)
The second most common lung cancer (20 to 30%) Slides 4, 39
Risk Factors
★ Smoking, the strongest association of any type Slide 39
Pathology
★ Central, often arising in a bronchus; frequent cavitation and obstruction; spreads by local invasion and by lymphangitic spread into the regional (hilar) lymph nodes Slides 30, 39–40
Clinical Manifestation
Silent until it obstructs the bronchus, then ★ cough, wheezing and hemoptysis; a large obstruction brings atelectasis and pneumonia; local invasion brings dysphagia and voice changes (laryngeal nerves); ★ hypercalcemia is its paraneoplastic syndrome Slides 39, 46
Diagnosis
Computed tomography: a large, cavitated lesion with a spiculated outline, nodular inner margins and lymphangitic spread; ★ unlike the other types, it can be caught by sputum cytology; calcium on the metabolic panel Slides 14, 30, 40
Treatment/Therapy
A combination of surgery, chemotherapy, immunotherapy and radiation (slide 40); slides 37 and 38 title gene-marker targeted therapy and immunotherapy “excluding squamous cell” Slides 37–38, 40
Mortality ★
Not covered in the lecture
Small cell lung cancer (SCLC)★ Professor emphasized

★ On his slide 49 list twice: how to recognize small cell, and the cancer that benefits most from radiotherapy (“If the cancer’s pretty limited, you can radiate it really effectively”). Prophylactic cranial irradiation: “We’re literally gonna radiate the brain just in case there’s metastasis.”

Name of Condition
Small cell lung cancer (SCLC), oat cell carcinoma Slide 4
Definition
A central lung carcinoma that infiltrates the mucosa; limited stage (one area, only local lymph nodes), extensive stage (spread beyond the local area) or combined (mixed with non-small cell types) Slide 41
Etiology (cause)
Associated with a lesion of the short arm of chromosome 3; can develop from APUD (amine precursor uptake and decarboxylation) cells that secrete polypeptide hormones Slide 41
Epidemiology (who)
15 to 20% of lung cancers; the type that typically causes the paraneoplastic syndromes Slide 4
Risk Factors
A genetic lesion of the short arm of chromosome 3; the general lung cancer risk factors, smoking above all Slides 3, 41
Pathology
★ Central; infiltrates the mucosa; a high cavitation rate once large enough for symptoms; histology: a fragile tumor, often crushed at biopsy, with small cells, no nucleoli and a high nuclear-to-cytoplasm ratio Slides 30, 41–42
Clinical Manifestation
Insidious: ★ over 70% are metastatic (liver, bone, brain) before detection; neuroendocrine paraneoplastic symptoms such as ★ the syndrome of inappropriate antidiuretic hormone (confusion, seizures, ataxia from a low sodium) Slides 41, 48
Diagnosis
Biopsy: crushed small cells with no nucleoli and a high nuclear-to-cytoplasm ratio; staged limited or extensive; brain magnetic resonance imaging (preferred over computed tomography) if prophylactic cranial irradiation is planned Slides 41–43
Treatment/Therapy
★ Responds better to chemotherapy and radiation than the three non-small cell types; radiation works best in limited stage. After a complete or partial response, ★ prophylactic cranial irradiation in limited stage, considered (with or without thoracic radiotherapy) in extensive stage; not recommended with poor performance status or impaired neurocognitive function. Immunotherapy is less effective (genetic variability) but becoming an option; two adjunct immunotherapies are approved. Radiotherapy effects: acute skin, mucosa and tissue changes (erythema, hyperpigmentation, ulceration risk), inflammation, hair loss, little nausea; chronic pulmonary fibrosis, cardiovascular damage (coronary artery disease, valvular disease, cardiomyopathy), lymphedema, neuropathy Slides 41, 43, 45
Mortality ★
Usually metastatic by the time of diagnosis (over 70% before detection); brain metastasis is likely enough that the brain is irradiated prophylactically Slides 30, 41, 43
Lung neuroendocrine (carcinoid) tumor6 not covered
Name of Condition
Lung neuroendocrine (carcinoid) tumor; bronchial carcinoid Slides 4, 48
Definition
One of the mixed and rare lung cancers; for lung causes, carcinoid syndrome comes mainly only from a bronchial carcinoid Slides 4, 48
Etiology (cause)
Not covered in the lecture
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
Release of serotonin from the cancer cells causes the carcinoid syndrome Slide 48
Clinical Manifestation
Carcinoid syndrome: cutaneous flushes and apparent cyanosis; cough, wheezing, dyspnea; diarrhea, cramps, nausea, vomiting; hepatomegaly; pulmonic and tricuspid valve thickening and stenosis, endocardial fibrosis; retroperitoneal and pelvic fibrosis Slide 48
Diagnosis
Not covered in the lecture
Treatment/Therapy
Not covered in the lecture
Mortality ★
Not covered in the lecture
Syndrome of inappropriate antidiuretic hormone (SIADH), paraneoplastic★ Professor emphasized2 not covered

★ “Small cell lung cancer, you can get SIADH, because that’s real … that patient may show up in the [emergency department] because of the confusion and seizures, and you work it up, and you’re like, oh, that’s lung cancer.”

Name of Condition
Syndrome of inappropriate antidiuretic hormone (SIADH), a paraneoplastic syndrome of small cell lung cancer Slides 46, 48
Definition
An endocrine paraneoplastic syndrome: excessive antidiuretic hormone (vasopressin) makes the body retain too much water Slides 46, 48
Etiology (cause)
★ Small cell lung cancer: the carcinoma cells develop from neuroendocrine cells in the tumor and produce excess antidiuretic hormone Slides 6, 48
Epidemiology (who)
Patients with small cell lung cancer, the type that typically causes paraneoplastic syndromes Slides 4, 48
Risk Factors
Small cell lung cancer Slide 48
Pathology
Excess antidiuretic hormone (vasopressin) causes water retention, hyponatremia and decreased serum osmolality Slide 48
Clinical Manifestation
★ Confusion, seizures, ataxia and other neurologic dysfunction, but no signs of peripheral or pulmonary edema, because it develops insidiously Slide 48
Diagnosis
Hyponatremia and decreased serum osmolality (the slides give no diagnostic criteria). A low sodium with high potassium, hypotension, fatigue and dizziness points instead to adrenal insufficiency from a metastasis Slides 13, 48
Treatment/Therapy
Not covered in the lecture
Mortality ★
Not covered in the lecture
Hypercalcemia, paraneoplastic★ Professor emphasized3 not covered

★ “A lot of times, your squamous cell will make your calcium, a big deal.”

Name of Condition
Hypercalcemia, a paraneoplastic syndrome of lung cancer Slide 46
Definition
An endocrine paraneoplastic syndrome: a raised calcium from the hormonal or cytokine effects of tumor tissue (the primary or a metastasis) Slide 46
Etiology (cause)
★ Particularly squamous cell carcinoma Slide 46
Epidemiology (who)
Particularly patients with squamous cell lung cancer Slide 46
Risk Factors
Squamous cell lung cancer Slide 46
Pathology
Secreted hormonal or cytokine effects of the tumor tissue (the slides give no more specific mechanism) Slide 46
Clinical Manifestation
Not covered in the lecture
Diagnosis
Calcium on the comprehensive metabolic panel in the lung cancer lab workup Slide 14
Treatment/Therapy
Not covered in the lecture
Mortality ★
Not covered in the lecture

Lecture 44 · Pleural Disorders

Rob Gray, DMSc, PA-C (guest lecturer) · 11 conditions · source: Pleural Disorders 2026.pptx

Note: Built from the slides plus the Zoom recording of the live lecture, which only chooses which facts to star. Slides 34, 58, 60, 74, 83, 97 and 119 are generated pictures with typing errors, read for meaning. He called the procedures a drive-by before the procedures course and said not to memorize the slide 97 laboratory thresholds, chest tube sizes or the flow charts; those are left out. Points the slides state two ways are given both ways or not stated: exactly 3 cm (slides 28, 55, 56), chest tube against aspiration for a large symptomatic primary pneumothorax (slides 55 and 58), tube or needle first in tension (slides 66 and 58), observation and air-leak timings (slides 53, 58, 60), mechanical ventilation as traumatic or iatrogenic (slides 61 and 17), the class of a pulmonary embolism, malignant or chylous effusion (slides 81, 83, 103, 111, 112), the first imaging test for an effusion (slides 90, 95, 97) and how long pleurodynia lasts (slides 118, 119). Current guidelines differ on the needle decompression site, pneumothorax sizing and the hemothorax threshold for thoracotomy; the slides are kept. Where he and a slide differ (pleurodesis, fremitus, the hemothorax film), the slide is kept. Dosing is left out.
Pleurisy2 not covered
Name of Condition
Pleurisy Slide 9
Definition
Inflammation of the parietal pleura causing pleuritic pain; not a diagnosis but a symptom Slide 9
Etiology (cause)
Idiopathic; trauma; infection (bacterial, viral); inflammatory disorders (systemic lupus erythematosus, rheumatoid arthritis); pneumothorax; pulmonary embolism; malignancy; drug reactions (methotrexate, amiodarone, hydralazine) Slide 10
Epidemiology (who)
Not covered in the lecture
Risk Factors
The underlying conditions; drugs: methotrexate (chemotherapy), amiodarone (antiarrhythmic), hydralazine (antihypertensive) Slide 10
Pathology
The pleural layers rub together and stimulate pain fibers in the parietal pleura, which has sensory innervation (intercostal and phrenic nerves; the visceral pleura has none); inflammation on the central diaphragm (phrenic nerve) refers pain to the shoulder or neck Slides 3, 9, 11
Clinical Manifestation
Well-localized sharp or stabbing chest wall pain worse with deep breathing, coughing, movement or sneezing; same-side shoulder or neck pain from the central diaphragm; tachypnea with limited chest wall expansion on the affected side; a pleural friction rub (grating, scratching, creaking; heard in both phases of respiration) that ★ disappears when the patient holds the breath, unlike a pericardial friction rub Slides 11–12
Diagnosis
Testing depends on the underlying condition. First consider myocardial infarction, pericarditis, aortic dissection, pneumonia, pneumothorax and pulmonary embolism; then rib fracture, costochondritis, vertebral fracture and nerve root pain from herpes zoster Slides 13–14
Treatment/Therapy
Treat the underlying condition; nonsteroidal anti-inflammatory drugs Slide 14
Mortality ★
Not covered in the lecture
Primary spontaneous pneumothorax★ Professor emphasized

★ “I like having a nice, easy number”: the 3 cm apex-to-cupola size; the stability list (“So don’t overthink it”); “don’t confuse gold standard with best initial test”; patient education “may be a question you get.”

Name of Condition
Primary spontaneous pneumothorax Slide 19
Definition
Air in the pleural space causing partial or complete lung collapse, with no thoracic trauma and no underlying lung abnormality Slides 16–17
Etiology (cause)
Rupture of apical blebs (under 1 cm, within the visceral pleura) or bullae (over 1 cm, under the visceral pleura), usually at the lung apex; air enters from the lung through the visceral pleura Slides 16, 18
Epidemiology (who)
Classically tall, thin young males, 20 to 40 years of age; male more than female; often at rest, sometimes during strenuous exercise; recurrence is common Slides 19, 21
Risk Factors
Tall, thin young male; smoking (a significant risk factor); family history (inherited association?) Slide 19
Pathology
Pleural pressure is normally negative (about 4 mm Hg below atmospheric), keeping the lung inflated against its tendency to collapse; air from a ruptured bleb or bulla lets the lung collapse. Patients typically have good pulmonary reserve, so severe distress is uncommon Slides 7–8, 18–19
Clinical Manifestation
Acute onset dyspnea and same-side acute pleuritic chest pain (severe, stabbing, worse with deep breathing); may be asymptomatic or only fatigued if small; cough is less common. Exam: tachypnea, tachycardia, decreased chest excursion, decreased or absent tactile fremitus, hyperresonance, diminished or absent breath and voice sounds on the affected side. Differential: myocardial infarction, pulmonary embolism, dissecting aortic aneurysm, pericarditis, pleurisy, muscle strain, costochondritis Slides 21–23, 25
Diagnosis
★ Initial test: a standard upright chest radiograph, showing the thin, sharp visceral pleural line, convex toward the chest wall, with no markings beyond it; on a supine film, the deep sulcus sign. ★ Size by the apex-to-cupola distance: under 3 cm is small (American College of Chest Physicians). Point-of-care ultrasound at the bedside (absent lung sliding; it does not size it). ★ Computed tomography is the gold standard for presence, size and location (and finds blebs and bullae) but impractical when time is critical. Arterial blood gas often unnecessary (usually hypoxemia and respiratory alkalosis). ★ Stable only with all of: respiratory rate under 24, heart rate over 60 and under 120, normal blood pressure, room-air oxygen saturation over 90%, speaking in whole sentences Slides 26, 28–30, 33–35, 51
Treatment/Therapy
Goals: evacuate the air, close the leak, prevent recurrence. Small (under 3 cm) with minimal symptoms: observation, analgesia, 100% oxygen by non-rebreather mask (speeds resorption), a repeat film at 6 to 12 hours, discharge if stable, a film at 24 to 48 hours. Small with significant dyspnea after analgesia: catheter aspiration (2nd intercostal space over the 3rd rib, midclavicular line), Heimlich valve or chest tube; a chest tube for failed observation (enlarging, respiratory rate over 30, saturation under 90%) or failed aspiration. Large (over 3 cm) with moderate or severe symptoms: chest tube (slide 55; the slide 58 picture gives simple aspiration or a small-bore catheter). Recurrent: video-assisted thoracoscopic surgery with pleurodesis. ★ Education: recurrence approaches 50% within three years; the best prevention is video-assisted thoracoscopic surgery with pleurodesis; stop smoking; delay air travel 7 to 14 days after resolution, confirmed by chest X-ray; avoid scuba diving; early surgical evaluation for pilots and divers; genetics referral for a family history Slides 36, 38, 52–55, 58–60
Mortality ★
Good pulmonary reserve, so severe respiratory distress is uncommon. Recurrence approaches 50% within three years (one-third of primary cases within one to two years; over 60% after a second episode; over 75% of recurrences on the original side) Slides 19, 59–60
Secondary spontaneous pneumothorax★ Professor emphasized

★ “Your classic board question for … a secondary spontaneous pneumothorax is like … tall, skinny, Marfan … 22-year-old”: Marfan syndrome is a connective tissue disease, so the pneumothorax is secondary.

Name of Condition
Secondary spontaneous pneumothorax Slide 20
Definition
Air in the pleural space with no thoracic trauma but with an underlying lung abnormality; a complication of underlying lung disease Slides 17, 24
Etiology (cause)
The underlying disease: chronic obstructive pulmonary disease (the most common; rupture of apical blebs), lung malignancy, mesothelioma, cystic fibrosis, pneumonia or tuberculosis, sarcoidosis (interstitial lung disease), ★ connective tissue disease such as Marfan syndrome Slides 17, 20
Epidemiology (who)
Patients with underlying lung disease, chronic obstructive pulmonary disease most often; in lung malignancy it may be the initial symptom Slide 20
Risk Factors
The underlying lung disease; ★ Marfan syndrome makes even a tall, thin young man’s pneumothorax secondary Slide 20
Pathology
Diminished pulmonary reserve from the underlying disease makes it a more serious event Slides 20, 24
Clinical Manifestation
The same symptoms as primary, generally greater because of less reserve; an infectious cause adds cough, fever, chills or fatigue; the same physical examination as primary (tachypnea, decreased excursion and fremitus, hyperresonance, diminished breath sounds) Slides 22–24
Diagnosis
The same imaging (upright chest radiograph first, computed tomography the gold standard, bedside ultrasound); arterial blood gas for severe underlying lung disease or persistent distress (oxygen saturation under 92%) despite treatment Slides 26, 33, 35
Treatment/Therapy
Most: chest tube insertion. Small (3 cm or less) and asymptomatic: observation, a chest tube for symptoms or a persistent air leak, hospitalization for monitoring. Video-assisted thoracoscopic surgery or thoracotomy with bleb stapling and pleural abrasion; chemical pleurodesis via chest tube if surgery is not an option. Catheter aspiration is contraindicated with underlying pulmonary disease. Hold positive-pressure therapy during an active air leak Slides 39, 56–57, 60
Mortality ★
More life-threatening than primary: diminished reserve requires more immediate intervention; high recurrence rates with greater consequences of recurrence (an indication for video-assisted thoracoscopic surgery) Slides 20, 49, 57
Traumatic pneumothorax (and iatrogenic)1 not covered
Name of Condition
Traumatic pneumothorax, closed or open (with iatrogenic pneumothorax) Slides 61–62
Definition
Pneumothorax with a history of thoracic trauma, blunt or penetrating: closed (no external wound) or open (a wound in the chest wall). Iatrogenic: injury to the pleura from a medical intervention Slides 17, 62
Etiology (cause)
Penetrating (gunshot or stab) wound or blunt chest trauma (a rib fracture tears the lung); cardiopulmonary resuscitation; mechanical ventilation (traumatic on slide 61, iatrogenic on slide 17). Iatrogenic: thoracentesis, subclavian vein catheter placement, bronchoscopy Slides 17, 61
Epidemiology (who)
Not covered in the lecture
Risk Factors
Chest trauma; medical interventions near the pleura Slides 17, 61
Pathology
Closed: air enters the pleural space from the lung through broken ribs or internal injuries. Open: a direct chest-wall wound lets air in during inhalation and can become a sucking chest wound Slide 62
Clinical Manifestation
A history of trauma (“Have you had any trauma?”); the presentation depends on the degree of lung collapse; a tension pneumothorax can follow Slides 16, 61, 63
Diagnosis
Bedside point-of-care ultrasound for unstable trauma; computed tomography (the gold standard) for trauma when time allows; upright chest radiograph Slides 26, 30, 34
Treatment/Therapy
Chest tube (thoracostomy tube; most commonly the 4th or 5th intercostal space, midaxillary line) to drain air or fluid; catheter aspiration is contraindicated in traumatic pneumothorax Slides 39, 41
Mortality ★
Tension pneumothorax is its life-threatening complication Slide 63
Tension pneumothorax★ Professor emphasized1 not covered

★ Recognize it and act: “At that point, I don’t have to prove it … It is reasonable to act”; his class poll answer was tracheal deviation away from the collapsed lung; the needle site: “For test purposes for now, that would be the right answer.”

Name of Condition
Tension pneumothorax Slide 63
Definition
A life-threatening complication of pneumothorax in which air enters the pleural space but cannot escape Slide 63
Etiology (cause)
A one-way valve traps air in the pleural space; taught as a complication of traumatic pneumothorax Slides 61, 63
Epidemiology (who)
Not covered in the lecture
Risk Factors
Traumatic pneumothorax (penetrating or blunt trauma, cardiopulmonary resuscitation, mechanical ventilation) Slides 61, 63
Pathology
Trapped air builds pressure: severe ventilatory compromise, ★ mediastinal shift to the contralateral side, decreased venous return to the heart and decreased cardiac output Slides 63–64
Clinical Manifestation
★ Hypotension, tracheal deviation (away from the collapsed lung) and neck vein distention; decreased or absent breath sounds; severe ventilatory compromise Slide 64
Diagnosis
★ A clinical diagnosis: time is critical, there is no time for the X-ray; the radiographic tension signs (mediastinal shift, diaphragmatic depression) should never be seen before it is recognized Slides 34, 65–66
Treatment/Therapy
A medical emergency. Immediate chest tube placement is ideal; if a chest tube is not readily available, immediate needle decompression (needle thoracostomy: ★ the side of the pneumothorax, 2nd intercostal space, over the 3rd rib, midclavicular line; consider body habitus), followed by a moderate or large chest tube (4th or 5th intercostal space, midaxillary line); admission. The slide 58 picture puts urgent needle decompression first, then the chest tube. Catheter aspiration is contraindicated Slides 39, 58, 66–68
Mortality ★
Life-threatening: severe ventilatory compromise with falling cardiac output and hypotension Slides 63–64
Hemothorax1 not covered
Name of Condition
Hemothorax (and hemopneumothorax) Slide 69
Definition
Blood in the pleural space: a pleural fluid hematocrit over 50% of the peripheral blood hematocrit (bloody fluid under 50% is a hemorrhagic effusion); strictly an exudative effusion Slide 74
Etiology (cause)
Trauma, the most common cause (injury to the heart or vasculature, lung parenchyma, or the intercostal, pulmonary or internal thoracic arteries); neoplasms; iatrogenic (thoracic surgery, invasive procedures); spontaneous vascular disruption; systemic causes (aneurysms, coagulopathies, arteriovenous malformations, endometriosis, neurofibromatosis) Slides 69, 74
Epidemiology (who)
Blunt or penetrating trauma causes the majority; hemopneumothorax occurs in 2 to 3% of spontaneous pneumothoraces Slide 74
Risk Factors
Chest trauma; thoracic surgery or invasive procedures; anticoagulation; coagulopathies Slides 69, 74
Pathology
Blood collects at the base of the pleural space; with air above it (hemopneumothorax) the fluid level is a straight line with no meniscus Slides 70–71
Clinical Manifestation
Not covered in the lecture
Diagnosis
Bedside ultrasound detects pleural fluid rapidly; hemopneumothorax: a straight air-fluid line, no meniscus; an effusion that enlarges during anticoagulation needs thoracentesis to rule out hemothorax; pleural fluid hematocrit over 50% of the blood hematocrit Slides 71, 74
Treatment/Therapy
Chest tube (typically the 4th or 5th intercostal space, midaxillary line) to evacuate and quantify the bleeding, the essential first step; blood loss over 200 mL per hour: thoracotomy (an open approach); surgery for persistent hemorrhage or hemodynamic shock Slides 69, 73–74
Mortality ★
Undrained blood is a nidus for infection; a retained hemothorax leads to empyema, fibrothorax and trapped lung Slide 74
Pneumomediastinum2 not covered
Name of Condition
Pneumomediastinum Slide 75
Definition
Air collected in the mediastinal tissues, occurring spontaneously or after procedures or trauma Slide 75
Etiology (cause)
Excessive intra-alveolar pressure rupturing alveoli that border the mediastinum; esophageal perforation; esophageal or bowel rupture with air dissecting from the neck or abdomen into the mediastinum Slide 75
Epidemiology (who)
Not covered in the lecture
Risk Factors
A sudden rise in intrathoracic pressure: violent coughing, vomiting, inhalation drug abuse (Valsalva); procedures or trauma Slides 75–76
Pathology
Air tracks through the mediastinal tissues; the heart beats against air-filled tissue (the Hamman crunch) Slides 75, 77
Clinical Manifestation
Nonspecific pleuritic chest or neck pain, sore throat, dyspnea, cough; palpable subcutaneous emphysema in the neck; Hamman crunch: substernal crackling or crepitance synchronous with the heartbeat Slides 76–77
Diagnosis
Not covered in the lecture
Treatment/Therapy
Assess and maintain the airway; treat the underlying cause if identified; conservative care (air is gradually absorbed, oxygen may speed absorption, avoid physical activity, analgesics); if severe, an emergent cardiothoracic surgery consult Slide 79
Mortality ★
Air is often gradually absorbed with conservative care; severe cases need an emergent cardiothoracic surgery consult Slide 79
Pleural effusion★ Professor emphasized1 not covered

★ Light’s criteria: “that makes great test questions” (the slide carries a lightbulb icon); “malignancy and CHF [congestive heart failure] are gonna be your frequent flyers”; of transudates, “Most of it’s gonna be CHF … Like, 90%.”

Name of Condition
Pleural effusion (transudate or exudate) Slide 81
Definition
Fluid accumulating in the pleural space: an exudate (high protein, from increased vascular permeability) if at least one of Light’s criteria is met, a transudate (low protein, from increased hydrostatic or reduced oncotic pressure) if all are absent Slides 101, 110
Etiology (cause)
Altered membrane permeability (inflammation, malignancy); reduced oncotic pressure (hypoalbuminemia: nephrotic syndrome, cirrhosis); increased capillary permeability (trauma, malignancy, inflammation, infection); increased hydrostatic pressure (heart failure); decreased or blocked lymphatic drainage (malignancy, trauma); peritoneal fluid crossing the diaphragm (cirrhosis, peritoneal dialysis). Exudates: pneumonia the most common cause, malignancy second (75% breast, lung, lymphoma), tuberculosis the leading cause worldwide. Transudates: ★ congestive heart failure in over 90%, cirrhosis with ascites, nephrotic syndrome, peritoneal dialysis Slides 81–82, 102–103, 111
Epidemiology (who)
Over 1.5 million patients a year in the United States; up to 62% of critically ill patients in intensive care; up to 30% have several causes at once; ★ congestive heart failure is the leading cause Slide 83
Risk Factors
Heart failure; cancer (malignant effusions can occur years after the diagnosis); hepatic disease; trauma; asbestos exposure; infection risk factors (diabetes, alcoholism, immunosuppression, poor dental hygiene); drugs (amiodarone, methotrexate, beta blockers) Slides 83–84
Pathology
Normally about 10 mL of fluid enters from parietal pleura capillaries and leaves by parietal pleura lymphatics, inflow equal to reabsorption; an effusion forms when that balance fails. Adhesions between the visceral and parietal pleurae form loculations (inflammatory causes such as empyema) Slides 4–5, 81, 94
Clinical Manifestation
Asymptomatic if small; dyspnea, dry cough and pleuritic chest pain (sharp, worse on deep inspiration, referred to the same-side shoulder or upper abdomen). Clues: edema, orthopnea, paroxysmal nocturnal dyspnea (heart failure); fever, purulent sputum (pneumonia); hemoptysis (malignancy); fever, night sweats, hemoptysis, weight loss (tuberculosis). Exam: no findings under 300 mL; asymmetrical expansion; trachea shifted away over 1000 mL; decreased tactile fremitus; dullness; diminished or absent breath sounds, bronchial toward the top; friction rub Slides 85–88
Diagnosis
Upright chest radiograph: 75 mL blunts the posterior and 175 mL the lateral costophrenic angle; the lateral decubitus film (effusion side down) has been replaced by ultrasound, which also guides thoracentesis; contrast chest computed tomography finds as little as 10 mL. Diagnostic thoracentesis (50 to 100 mL) for a new effusion with no clinical cause: protein, lactate dehydrogenase, white cell count with differential, Gram stain, cytology, culture; appearance alone is not diagnostic. ★ Light’s criteria: an exudate if at least one of pleural to serum protein over 0.5, pleural to serum lactate dehydrogenase over 0.6, or pleural lactate dehydrogenase over two-thirds of the upper limit of normal serum lactate dehydrogenase Slides 90–91, 93, 95–96, 98–99, 101
Treatment/Therapy
Treat the underlying disorder (diuretics first for heart-failure transudates); diagnostic or therapeutic thoracentesis (relieves dyspnea and tests whether the lung expands); chest tube; pleurodesis for recurrent malignant effusions (lung, breast, ovarian) as palliative care, for an expandable lung; an indwelling tunneled pleural catheter, placed as an outpatient and drained at home, for short prognoses, a non-expandable lung or rapidly recurring fluid Slides 97, 113–114
Mortality ★
Not covered in the lecture
Chylothorax2 not covered
Name of Condition
Chylothorax Slide 104
Definition
Accumulation of lipid from chyle (lymph fluid) in the pleural space from thoracic duct disruption Slide 104
Etiology (cause)
Trauma, most commonly thoracic surgery; tumors in the mediastinum Slide 105
Epidemiology (who)
Not covered in the lecture
Risk Factors
Thoracic surgery or other chest trauma; mediastinal tumors Slide 105
Pathology
Disruption of the thoracic duct, which carries chyle up from the cisterna chyli, lets chyle collect in the pleural space Slide 104
Clinical Manifestation
Not covered in the lecture
Diagnosis
Thoracentesis: milky white fluid with elevated triglycerides; with no obvious trauma, a lymphangiogram and computed tomography to assess the mediastinum Slides 98, 105
Treatment/Therapy
Chest tube or intermittent thoracentesis, avoiding excessive drainage; octreotide (mimics somatostatin, slows gastrointestinal secretions) decreases chyle drainage; fewer long-chain triglycerides in the diet decrease chyle drainage (they are absorbed through the lymphatic system) Slide 106
Mortality ★
Excessive chyle loss can impair nutritional status Slide 106
Empyema2 not covered
Name of Condition
Empyema Slide 107
Definition
Purulent fluid in the pleural space Slide 107
Etiology (cause)
Bacterial pneumonia with a parapneumonic effusion, the most common precursor: microorganisms infect the pleural space, causing a complicated parapneumonic effusion or empyema; a retained hemothorax can also lead to empyema Slides 74, 107
Epidemiology (who)
Not covered in the lecture
Risk Factors
Pneumonia with a parapneumonic effusion; the infection risk factors for effusion (diabetes, alcoholism, immunosuppression, poor dental hygiene); a retained hemothorax Slides 74, 83, 107
Pathology
Pleural inflammation causes adhesions between the visceral and parietal pleurae, forming loculations; fibrin membranes on ultrasound and at thoracoscopy Slides 94, 109
Clinical Manifestation
Suspect it when pneumonia symptoms do not resolve with therapy; pleuritic pain Slide 108
Diagnosis
Purulent material on thoracentesis Slides 98, 108
Treatment/Therapy
Prompt therapy is critical: drainage and antibiotics; treat the underlying disease; analgesia for pleuritic pain Slides 107–108
Mortality ★
Not covered in the lecture
Pleurodynia
Name of Condition
Pleurodynia (Bornholm disease) Slides 116, 119
Definition
A viral myalgia of the striated intercostal muscles Slide 116
Etiology (cause)
Often coxsackie B virus (an RNA (ribonucleic acid) enterovirus), also echoviruses, typically after an upper respiratory or gastrointestinal infection Slides 116, 119
Epidemiology (who)
Adults (pleuritic pain) and children (abdominal pain); a summer peak; spread by fecal-oral contamination and contaminated water Slides 117, 119
Risk Factors
Exposure to coxsackievirus or echovirus by the fecal-oral route or contaminated water Slide 119
Pathology
The virus targets the striated intercostal muscles, causing inflammation or necrosis and frequent elevations of serum creatine kinase Slide 116
Clinical Manifestation
Acute onset of fever and pleuritic pain (adults) or abdominal pain (children); paroxysms of severe, knife-like pain lasting 15 to 30 minutes with diaphoresis and tachypnea; splinting of the chest during attacks; tender involved muscles Slide 117
Diagnosis
Elevated serum creatine kinase; a chest radiograph, usually normal, rules out other causes of chest pain Slides 116, 118
Treatment/Therapy
Supportive: nonsteroidal anti-inflammatory drugs and heat to the affected muscles; prevention by hand hygiene and pool chlorination Slides 118–119
Mortality ★
Symptoms resolve but may recur a few days later; a self-limited, benign course without long-term sequelae; orchitis and aseptic meningitis in under 10% Slides 118–119

Lecture 45 · Acid-Base Disorders II

Megan B. Finck, MMS, PA-C · 5 conditions · source: PAJ5510 Acid Base Disorders II MBF2026sc.pptx

Note: Built from the slides plus the lecture recording, which only chooses which facts to star; it adds no content. The four simple disorders are the conditions, plus the mixed disorders (slides 26-30, 49-50). This deck repeats Lecture 34's foundations with its own numbers: anion gap normal 6 to 12 here (9 to 15 in Lecture 34). Points the slides state two ways are given both ways or not keyed: the carbon dioxide range (36 to 44 on slide 6, 35 to 45 on slide 10), the anion gap cut-offs (above 12 on slide 44, above 20 suggesting a primary metabolic disorder on slide 26), the 1.3 ratio (slide 24) against the Winter formula (slide 49), the group of alkaline drugs and exogenous alkali (slide 53), pulmonary embolism under respiratory acidosis (slide 32) against lung disease under respiratory alkalosis (slide 39), and diabetic ketoacidosis (raised gap) against its recovery (normal gap, slide 47). The slides write the change in bicarbonate as the lab result minus normal; the size of the fall from 25 is used. Her worked cases that are not on the slides, and her rounding shortcuts, are not used. The slides give no incidence or mortality figures.
Respiratory acidosis★ Professor emphasized4 not covered

★ Acute versus chronic is read from how far the bicarbonate has risen (1 versus 3.5 per 10 mm Hg); stop respiratory depressants such as narcotics; give oxygen carefully to chronic retainers.

Name of Condition
Respiratory acidosis (acute or chronic) Slides 11, 31
Definition
Decreased pH with increased carbon dioxide, from decreased alveolar ventilation, never increased carbon dioxide production; may be acute or chronic Slides 10–11, 31
Etiology (cause)
Central nervous system depression (sedatives, central nervous system event); neuromuscular disorders (myopathies, neuropathies); kyphoscoliosis, Guillain-Barré syndrome, myasthenia gravis, botulism, polymyositis; impaired lung motion (hemothorax, pneumothorax); thoracic cage injury (flail chest); acute airway obstruction (upper airway, laryngospasm, bronchospasm); severe pneumonia or pulmonary edema; ventilator dysfunction; obesity-hypoventilation syndrome; pleural effusion; lung disease (chronic obstructive pulmonary disease, acute respiratory distress syndrome) Slide 32
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
The body raises bicarbonate by cell buffering and increased acid secretion, two mechanisms over different time periods. Compensation is renal. ★ Acute: bicarbonate rises 1 mEq/L for every 10 mm Hg rise in carbon dioxide; chronic (after 24 to 48 hours): 3.5 mEq/L per 10 mm Hg, through urinary excretion of titratable acid and ammonium. ★ Compensation will not fully correct the pH Slides 23–24, 31, 33–34
Clinical Manifestation
Not covered in the lecture
Diagnosis
Arterial blood gas and electrolytes: low pH, high carbon dioxide. To tell acute from chronic, compare the measured bicarbonate with the expected bicarbonate at each rate (slide 35 example: carbon dioxide 80 mm Hg) Slides 10, 35, 56
Treatment/Therapy
Treat the underlying condition; look at medications and ★ stop respiratory depressants (narcotics, benzodiazepines). Acute or severe impairment (carbon dioxide above 80 mm Hg with life-threatening hypoxia, oxygen below 40 mm Hg): adequate ventilation (emergency airway, mechanical ventilator), clear secretions and assure airway patency, give oxygen. Chronic: similar but with ★ careful oxygen administration; a rapidly falling carbon dioxide may trigger alkalosis complications (cardiac arrhythmias, reduced cerebral perfusion, seizures) Slides 36–37
Mortality ★
Not covered in the lecture
Respiratory alkalosis4 not covered
Name of Condition
Respiratory alkalosis (acute or chronic) Slides 11, 38
Definition
Increased pH (above 7.45) with decreased carbon dioxide Slides 11, 38
Etiology (cause)
Anxiety; hypoxia; high altitude (physiologic respiratory alkalosis); lung disease with or without hypoxia; decreased lung compliance (interstitial fibrosis); central nervous system disease; catastrophic central nervous system event (intracerebral hemorrhage) Slide 39
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
Increased ventilation lowers carbon dioxide. Compensation is renal: bicarbonate falls 2 mEq/L per 10 mm Hg fall in carbon dioxide acutely and 5 mEq/L chronically; alkalosis shifts potassium into cells (hypokalemia) and increases hemoglobin's oxygen affinity (less oxygen delivered to tissues) Slides 5, 22, 24
Clinical Manifestation
Not covered in the lecture
Diagnosis
High pH with low carbon dioxide on the arterial blood gas Slides 10–11
Treatment/Therapy
Mild (pH below 7.50): treatment usually not required. Treat pain, anxiety, fever, infection or salicylate overdose; mindful breathing to help control hyperventilation. On mechanical ventilation: decrease minute volume (fewer breaths per minute or a smaller tidal volume) Slide 40
Mortality ★
Not covered in the lecture
Metabolic acidosis★ Professor emphasized2 not covered

★ A big anion gap is always metabolic; correct the gap for albumin; use the Winter formula to find a respiratory partner and the change in gap against the change in bicarbonate to find a metabolic one.

Name of Condition
Metabolic acidosis (increased, normal or decreased anion gap) Slides 11, 41
Definition
Decreased pH with decreased bicarbonate: an excess of acid to buffer or a net loss of bicarbonate from extracellular fluid Slides 11, 41
Etiology (cause)
Increased anion gap (MUDPILES): methanol, metformin; uremia; diabetic, alcoholic or starvation ketoacidosis; paraldehyde, propylene glycol; isoniazid, iron; lactic acidosis; ethylene glycol; salicylates, starvation; also renal failure, rhabdomyolysis. The Big 4: ketoacidosis, lactic acidosis (poor tissue perfusion, tissue necrosis, severe anemia, trauma), renal failure (acute or chronic), toxins (salicylates, alcohols, 5-oxoproline from acetaminophen). Normal anion gap (USEDCAR): ureteral diversion, saline infusion, exogenous acid, diarrhea, carbonic anhydrase inhibitors, adrenal insufficiency, renal tubular acidosis; also chlorine gas exposure, hyperalimentation (total parenteral nutrition) Slides 43–46
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
Compensation is respiratory: carbon dioxide is lowered by increasing respiration. Normal-gap acidosis is loss of bicarbonate (diarrhea, recovery from diabetic ketoacidosis, pancreatic fluid loss, unadapted ileostomy, carbonic anhydrase inhibitors), chloride retention (renal tubular acidosis, ileal loop bladder) or acid given (hydrochloric acid equivalent, ammonium chloride, arginine and lysine in parenteral nutrition). Acidosis shifts potassium out of cells (hyperkalemia) and lowers hemoglobin's oxygen affinity Slides 5, 24, 41, 47
Clinical Manifestation
Mainly the underlying disorder; compensatory hyperventilation; ★ Kussmaul breathing (deep, regular, sighing breaths) in severe acidosis Slide 42
Diagnosis
★ Anion gap = sodium - (bicarbonate + chloride), normal 6 to 12 (average about 10); the gap can be abnormal with normal electrolytes. ★ Correct for albumin: add 2.5 for each 1 g/dL below 4.5 (albumin 3.5 to 5.5 g/dL). Increased gap: think above 12, metabolic anions, renal failure, toxins; ★ a large gap is never compensation for a respiratory disorder alone. Decreased gap (below 6): hypoalbuminemia, plasma cell dyscrasias, bromide. ★ Winter formula: expected carbon dioxide = 1.5 x bicarbonate + 8, plus or minus 2 Slides 7–8, 26, 44, 48–49
Treatment/Therapy
Treat the underlying condition; therapy to normalize the pH may be warranted when the pH is below 6.7 (unsustainable), along with treatment of the cause Slide 12
Mortality ★
A pH below 6.7 or above 7.6 is unsustainable: it may cause cardiac hypocontractility or irritability, seizures, cerebral edema and metabolic disturbances Slide 12
Metabolic alkalosis★ Professor emphasized2 not covered

★ Urine chloride splits saline-responsive from saline-unresponsive; the hypokalemia of alkalosis is a shift, so do not overcorrect.

Name of Condition
Metabolic alkalosis (saline-responsive or saline-unresponsive) Slides 11, 51
Definition
Increased pH (above 7.45) with decreased hydrogen ions and increased bicarbonate Slides 11, 51
Etiology (cause)
Saline-responsive: volume contraction; diuretics (sodium reabsorption, hydrogen ion secretion); vomiting or gastric suction (loss of gastric hydrochloric acid); ingestion of alkaline drugs (sodium bicarbonate); post-hypercapnia. Saline-unresponsive, normotensive: severe potassium depletion; hypoparathyroidism and hypercalcemia. Saline-unresponsive, hypertensive: primary aldosteronism; exogenous alkali; mineralocorticoids; licorice Slide 53
Epidemiology (who)
Not as common as metabolic acidosis Slide 51
Risk Factors
Not covered in the lecture
Pathology
Compensation is respiratory: carbon dioxide rises 0.75 mm Hg per 1 mEq/L rise in bicarbonate; alkalosis shifts potassium into cells (hypokalemia) Slides 5, 24
Clinical Manifestation
Mainly the underlying disorder; hypokalemia may cause weakness and hyporeflexia; rarely tetany and neuromuscular irritability Slide 52
Diagnosis
High pH with high bicarbonate. ★ Urine chloride differentiates the types: lower in saline-responsive (below 25 mEq/L), higher in saline-unresponsive (above 40 mEq/L) Slides 10–11, 51
Treatment/Therapy
Treat the underlying condition; if the cause is unclear, measure urinary chloride to narrow the differential; discontinue possible contributors (diuretics, nasogastric suction, corticosteroids); treat fluid and potassium deficits if needed; ★ don't overcorrect. If corticosteroids are needed: decrease the dose or change to one with less mineralocorticoid activity (prednisone or methylprednisolone rather than cortisone or hydrocortisone). Consider excess alkali intake, glucose ingestion after starvation, high-dose penicillin, profound potassium depletion, endogenous mineralocorticoid excess Slides 54–55
Mortality ★
Not covered in the lecture
Mixed acid-base disorders★ Professor emphasized3 not covered

★ Compensation never fully corrects the pH, so a normal pH with abnormal values points to a mixed disorder; only one respiratory disorder at a time; circle back to the patient.

Name of Condition
Mixed acid-base disorders Slide 4
Definition
More than one primary disturbance at the same time (a simple disorder is one primary disturbance and its compensation). ★ Cannot have more than one primary respiratory disorder Slides 4, 23
Etiology (cause)
Slide examples: metabolic acidosis with respiratory alkalosis (lactic acidosis, sepsis in the intensive care unit); metabolic acidosis with respiratory acidosis (severe pneumonia, pulmonary edema); metabolic alkalosis with respiratory alkalosis (liver disease and diuretics); metabolic alkalosis with respiratory acidosis (chronic obstructive pulmonary disease on diuretics); metabolic acidosis with metabolic alkalosis (uremia with vomiting); high-gap with normal-gap metabolic acidosis (diarrhea and lactic acidosis, toluene toxicity, treatment of diabetic ketoacidosis) Slides 28–30
Epidemiology (who)
Not covered in the lecture
Risk Factors
Not covered in the lecture
Pathology
★ Compensation will not fully correct the pH; inadequate or excessive compensation points to a mixed disorder Slides 23, 26
Clinical Manifestation
Most important when the patient is critically ill and the cause is not yet clear; determining the disorder narrows the differential Slide 9
Diagnosis
★ A normal pH can mean no abnormality or a mixed acid-base disorder. ★ Winter formula: carbon dioxide above expected = concurrent respiratory acidosis; below = concurrent respiratory alkalosis. ★ Change in anion gap (from 10) against change in bicarbonate (from 25): equal = metabolic acidosis only; gap change larger = concurrent metabolic alkalosis (only detectable if the gap is high); bicarbonate change larger = check the change in chloride; bicarbonate change equal to gap change plus chloride change = concurrent increased-gap and normal-gap metabolic acidosis. Metabolic alkalosis with respiratory alkalosis: carbon dioxide does not rise as predicted, pH higher than expected; with respiratory acidosis: carbon dioxide higher than predicted, pH normal. Examine the patient again: do the clinical findings support the analysis? Slides 27–30, 49–50, 57–58
Treatment/Therapy
Identify the underlying causes and treat both diagnoses Slide 63
Mortality ★
Not covered in the lecture